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Abstract 
Interactions between proteins play a key role in nearly all cellular process, and therefore, 
disruption of such interactions may lead to many different types of cellular dysfunctions. Hence, 
pathologic protein-protein interactions (PPIs) constitute highly attractive drug targets and hold 
great potential for developing novel therapeutic agents for the treatment of incurable human 
diseases. Unfortunately, the identification of PPI inhibitors is an extremely challenging task, since 
traditionally used small molecule ligands are mostly unable to cover and anchor on the extensive 
flat surfaces that define those binary protein complexes. In contrast, large biomolecules such as 
proteins or peptides are ideal fits for these so-called “undruggable” sites. However, their poor 
pharmacokinetic properties have limited their application as therapeutics. In this context, 
peptidomimetic molecules have emerged as an alternative and viable solution to this problem, 
since they conserve the architectural and structural features of peptides and also exhibit 
substantially improved pharmacokinetic profiles. Given the great promise of this class of 
compounds as therapeutics, new protocols granting easy access to them continue to be of great 
interest.  This thesis describes the development of an efficient solid phase methodology for the 
chemoselective synthesis of bisthioether stapled peptides of multiple architectures and its 
application to discovering three families of potent allosteric inhibitors of the polycomb repressive 
complex 2 (PRC2) of proteins.  
  v 
PRC2 is a multimeric complex consisting of four core proteins: EZH2, EED, SUZ12 and 
RBAP46/RBAP48, which is involved in the initiation of gene repression through its 
methyltransferase activity, specific for lysine 27 on Histone H3 (H3K27).  The enzymatic activity 
of PRC2 is conferred by the catalytic SET domain of EZH2, but also to the other core components 
of the complex. Hence, a catalytically active PRC2 complex must contain EZH2 and at least EED 
and SUZ12, which underscores the role of the latter proteins as scaffolds for the proper assembly 
of PRC2 into its bioactive conformation. The biological relevance of PRC2 proteins is highlighted 
by their known role in the development and progression of different types of cancers, and thus 
targeting them has emerged as a high-priority strategy in the field of cancer epigenetics. 
The thesis first describes the development of an innovative solid phase approach for the 
preparation of bisthioether stapled peptides of multiple architectures, including single-, double-
turn and double stapled peptides. This methodology allows for ligation with all-hydrocarbon 
linkers of various lengths, avoiding the use of unnatural amino acids and expensive catalysts, and 
affords cyclopeptides with improved bioactive conformation and remarkable resistance to 
proteolytic degradation. Next, we describe the rational design, synthesis and biological evaluation 
of three new families of allosteric inhibitors of PRC2 function, targeting for the first time three 
protein interfaces in PRC2 that are crucial for its proper assembly and function: the intramolecular 
SANT1L/SBD interaction of EZH2, the SUZ12-VEFS/EZH2-SANT2 binary complex and the 
interaction between SUZ12-NBE domains. Remarkably, these inhibitors have demonstrated cell 
permeability, potent activity in vitro and in physiological conditions, as well as strong 
antiproliferative effects on Caki-1 renal cancer cells, which highlights their potential as novel 
therapeutics for the treatment of PRC2-dependent human cancers.  
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Chapter I. Peptidomimetics as Chemical Probes to Target 
Intracellular Protein-Protein Interactions 
 
1.1 Background and Significance 
Protein-protein interactions (PPIs) are crucial for a plethora of cellular processes and thus 
for the proper functioning of living cells and organisms. Their dysregulation can lead to many 
types of cellular dysfunctions which can further develop into diseases, hence, targeting specific 
PPIs is currently one of the most attractive approaches for designing potential therapeutics1-4. The 
“undruggable” nature of these attractive macromolecular interactions, however, have made them 
particularly challenging targets. PPIs involve large, flat and featureless surfaces, ranging from 
1500 to 3000 A2 and lacking well-defined architectural features such as hydrophobic pockets or 
clefts5-7. Thus, these recognition events result from a collection of scattered smaller interactions or 
hot-spots, which are structurally unsuitable for small molecules ligands, traditionally used by 
medicinal chemists8-11. Indeed, effectively disrupting PPIs requires the use of larger molecules, 
capable of covering extensive molecular areas and establishing contacts with multiple hot spots 
simultaneously.  Peptides are great candidates for such purposes since they are large enough to 
cover lengthy contact surfaces and also have the potential to recapitulate the shape and 
conformation of natural binding sites12-14. In addition, they are easily accessible, offer high 
structural diversity and low toxicity. Unfortunately, high susceptibility to protease degradation and 
often poor cell permeability and binding affinities, have limited their therapeutic applications, 
especially for targeting intracellular PPIs15-16.  
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Extensive efforts have been made to overcome the poor pharmacokinetic properties of 
peptides and to transform them into more ideal drug candidates11-14, 17. As a result of this work, 
several approaches yielding peptidomimetic molecules have been discovered. These synthetically 
modified peptides, with improved pharmacokinetic profiles, are designed to mimic their bioactive 
parent sequences and have encountered applications in a wealth of biological targets, showing 
great promise as potential modulators of undruggable intracellular PPIs11, 13-15. Several reviews in 
the literature have discussed the progress in the field, primarily focusing on either specific families 
of compounds or in their biological applications11-18. Since the number of relevant reports covering 
this attractive research area continues to grow, we present here a wider comprehensive updated 
overview focused on both the synthesis and the biological evaluation of two major groups of 
biologically active peptidomimetic derivatives: “stapled peptides”, designed to mimic alpha 
helical motifs of protein domains; and cyclopeptides resulting from long range macrocyclizations, 
aimed at mimicking beta sheets and other turn motifs. Some relevant biophysical properties of 
such compounds, including their cellular uptake and proteolytic stability are discussed as well.  
 
1.2 Stapled Peptides 
Peptide stapling has emerged as one of the most successful strategies to produce potent 
peptidomimetic inhibitors of intracellular PPIs18-20. This methodology aims primarily at 
mimicking native-helical domains, a recurrent protein motif that serve as a fundamental 
recognition unit in over 40% of naturally occurring PPIs. The idea behind stapling a peptide lies 
in tethering the side chain of a residue i with that of another residue at position i+4 or i+7 in the 
sequence, since these residues protrude on the same face of the helix (Figure 1.2.1). By 
incorporating a covalent “staple” the peptide is induced into its bioactive -helical conformation, 
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that in addition, is stabilized by intramolecular hydrogen bonding between the amide bonds on 
opposite sides of the helix21. This conformational restriction effectively improves not only the 
helical character of a given peptide sequence, and thus, its binding affinity to the protein target, 
but also its resistance to proteolysis and cell permeability properties22-23. Several factors impact 
the extent of such improvement, particularly the length of the peptide sequence, as well as the 
position and physicochemical properties of the staple. A series of chemical strategies to 
accomplish peptide stapling have been reported to date. Next, we summarize them and further 
discuss the pharmacokinetic properties of the corresponding likers used for ligation, as well as 
some examples demonstrating the wide range of biological applications for which this promising 
new class of compounds have been successfully applied.  
 
 
 
Figure 1.2.1 The stapled peptide approach (A) Single turn stapled peptide (i, i+4) (B) Double turn 
stapled peptide (i, i+7). 
 
 
Linker
(i, i + 4)
Linker
(i, i + 7)
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1.2.1 Synthetic Methods Yielding Stapled Peptides 
The incorporation of all-hydrocarbon staples by means of the ring-closing metathesis 
(RCM) reaction is the most widely used method for stabilizing α-helical peptides. This approach 
was first developed by Blackwell and Grubbs, who established an efficient solid phase procedure 
for the macrocyclization of linear peptides containing O-allylserine residues, via the ruthenium-
catalyzed RCM reaction24. An extension of this work by Verdine and colleagues further allowed 
for ligation of alkenyl side chains of ,-disubstituted unnatural amino acids, previously 
incorporated at positions (i, i+3), (i, i+4) and (i, i+7) in the corresponding linear sequences, under 
the same RCM stapling conditions25 (Scheme 1.2.1). This latter methodology constituted a major 
breakthrough in the field since it yielded macrocyclic -helical peptides with remarkable 
resistance to proteolytic degradation, significantly improved alpha-helical character and enhanced 
affinity to their protein targets. Verdine’s pioneer stapling technology has been applied to generate 
multiple all-hydrocarbon stapled peptide inhibitors of intracellular PPIs with a wide variety of 
biological applications22, 26-28. Moreover, it has been recently applied to generate the first stapled 
peptide drugs entering clinical trials29.  
Scheme 1.2.1 Schematic representation for the synthesis of stapled peptides using the olefin 
metathesis reaction. Incorporation of -methyl, -alkenyl amino acids followed by stapling 
through ring closing metathesis affords all-hydrocarbon stapled peptides of various architectures. 
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Several other synthetic approaches allow for peptide stapling using alternative chemistries 
and linkers with diverse topologies, including ligation of cysteine-thiols, disulfide bridges, 
lactamization reactions, nitrogen arylation, formation of oxime or hydrazones linkers, Cu(I) 
catalyzed azide-alkyne cycloadditions and metal-catalyzed arylation reactions30.   
The ligation of cysteine residues exploits the nucleophilicity of the thiol functional group 
to facilitate substitution reactions over highly reactive electrophiles, affording bisthioether stapled 
peptides tethered mainly by different aromatic ring scaffolds31-32. Several bis-aromatic 
electrophiles have been successfully used for this purpose, including photosensitive 4,4’-
bis(iodoacetamide)azobenzene33-34’-dibromo-m-xylene35-36, 4,4’-bis(chloroacetamide) 
biphenyl-acetyl-ene37 and 4,4’-bis(bromomethyl)biphenyl (Scheme 1.2.2)38. Other approaches 
have used 1,3-dichloro-acetone39, perfluoaryl40, tetrazine41 and bis-palladium aryl derivatives42.  
 
 
Scheme 1.2.2 Solution phase approaches for the synthesis of bisthioether stapled peptides using 
highly reactive dihaloelectrophiles.  
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for example, Jo et al. reported that the direct bis-alkylation of cysteine thiols with dibromo and 
diiodoalkanes in solution phase only affords the corresponding unreacted linear precursors mixed 
with disulfide-bridged peptides35. An extension of this solution protocol including TCEP as 
reducing agent, longer reaction times and higher temperatures has allowed the preparation of i+4 
and i+7 bisthioether stapled peptides linked through eight and nine methylene groups, 
respectively43. A similar solution phase approach, using commercially available 3,3-
bis(bromomethyl)oxetane as electrophile, has been recently applied to the efficient stapling of 
cysteines residues on peptides and proteins under biocompatible aqueous conditions44.   
An elegant alternative to the two-component bis-alkylation of cysteine thiols with poorly 
electrophilic aliphatic cross-linkers has been recently reported by Wang et al., who have applied a 
photoinduced thiol-ene radical reaction with ,-dienes to produce bis-thioether stapled 
macrocycles bearing hydrocarbon braces with five, seven and nine methylene groups (Scheme 
1.2.3)45.  
 
Scheme 1.2.3 Solution synthesis of bisthioether stapled peptides by means of a two-component 
thiol-ene reaction between a fully deprotected peptides and various dienes.  
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initiator as reaction catalyst. Thiol/yne stapling can also be carried out through a similar one-
component radical reaction with alkynes, affording vinyl sulfide linked cyclopeptides46.  
 
Recently, the more reactive selenocysteine (as compared to cysteine) unnatural amino acids 
have been successfully used for peptide stapling through a selenoether linkage. This solution phase 
protocol allows for ligation with a wide range of alkylating reagents including poorly electrophilic 
dihaloalkanes (Scheme 1.2.4)47. Likewise, stapling can also be achieved by means of disulfide 
bridges48-49. Indeed, this was one of the first reported ligation techniques. However, due to the 
instability of the disulfide linkage in reducing environments this method has encountered only 
limited application. A recent example uses a reversible reaction for stapling BID and RNase S 
modified peptides through either oxidized disulfides or a dibromomaleimide crosslinker50. The 
resulting macrocycles show resistance to proteolysis, enhanced -helical conformation and 
improved biological activity as compared to their respective linear counterparts. 
 
Scheme 1.2.4 Solution synthesis of bis-selenoether stapled peptides by means of a two-component 
reaction between fully deprotected selenocysteine-substituted peptides and various electrophiles.  
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Lactamisations have also been extensively applied for peptide stapling at positions (i, i+4) 
through amide-bond forming intramolecular cyclization of, for example, Lys/Asp, Orn/Lys and 
Asp/Glu residues (Scheme 1.2.5a)51-53. An advantage of this approach is that it uses natural amino 
acids, however, it also requires orthogonal protection of the residues participating in the ligation 
step. Nonetheless, several groups have applied this technique to generate cyclopeptides with 
superior -helicity and biological activity, mostly targeting extracellular or membrane-bound PPIs. 
More recently, lysine-based substituted peptides have also been used as scaffolds to generate aryl-
tethered stapled peptides, through an N-arylation intramolecular macrocyclization and using 
several aromatic bis-electrophiles (Scheme 1.2.5b)54.  
 
 
Scheme 1.2.5 (a) Peptide stapling through lactamisation, a polar amide bond can be 
chemoselectively formed by orthogonally protecting both the amino and the carboxylate functional 
groups used for the macrocyclization (b) Nitrogen arylation of unprotected peptides allows cross-
linking through lysine-based nucleophiles, using highly reactive aryl electrophiles.  
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dialkynyl linkers under Cu(I) catalysis, affording bis-triazole tethered peptides (Scheme 1.2.6)28, 
55-58. Similarly, peptide stapling has also been accomplished by popular metal catalyzed C-C bond 
formation reactions. Thus, using the Suzuki-Miyaura methodology Meyer and colleagues have 
prepared bi-aryl linked cyclopeptides, from linear sequences containing borylated phenyalanine 
residues59. Likewise, Mendive-Tapia et al. have reported an intramolecular cross coupling ligation 
between iodinated phenylalanine or tyrosine precursors and tryptophan residues, through a C-H 
activation process catalyzed by Pd(II). This approach yields aryl-tryptophan linked macrocycles 
of various sizes and is carried out in both solution and on solid phase60. 
 
 
Scheme 1.2.6 (a) Cu(I)-catalyzed cycloaddition between bis-alkynes and a bis-azide 
functionalized peptide allows for peptide cross-linking through a bis-triazole linker (b) Suzuki-
Miyaura coupling affords stapled peptides with a biphenyl ring spacer.  
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Table 1.1 Summary of Stapling Methodologies 
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Overall, the number of approaches applied to stabilize peptide -helical structures has 
expanded significantly in the last few years and continues to grow fast. The versatility of these 
methods has undoubtedly facilitated the identification of multiple bioactive cyclopeptides, 
particularly useful to target intracellular intractable PPIs. Each of them has their own strengths but 
they also have some associated weaknesses. For example, most protocols require the use of 
expensive unnatural amino acids which increases significantly the overall cost of the process. An 
exception to this problem is to exploit the reactivity of native cysteine residues.  Other significant 
drawbacks include the need for metal catalysis, high boiling point organic solvents (for solution 
phase methods) and photo-induced activation as in the case of the thiol-ene/yne ligations. Another 
major difference comes from the topology of the staple resulting from the ligation step, which may 
have a significant impact on the induction of the -helical conformation of the macrocycle. This 
feature has been recently explored by De d. Araujo et al. who tested the degree of helical induction 
in a model pentapeptide ligated with six different linkers61. These studies showed that 
lactamisation led to the greatest increase in -helicity closely followed by the all-hydrocarbon 
staple and triazole spacers, whereas mono- and bis-thioether linkages showed lower ability to 
stabilize the peptide -helical conformation. More comprehensive studies in larger macrocycles 
and using other stapling chemistries will provide additional valuable insights into this critical 
factor for stapled peptide’s design.  
In summary, the field of stapled peptide synthesis has attracted significant interest since 
the discovery of the RCM stapling technology. The success and potential of this class of 
compounds has been already extensively demonstrated. Therefore, novel synthetic methodologies 
that expand the scope of the current approaches and grant easy access to stapled peptides continue 
to be of great interest in the field. 
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1.2.2 Cell Permeability of Stapled Peptides 
Over 95% of the peptides entering clinical trials in 2016 were directed at GPCRs and other 
extracellular targets, including receptor tyrosine kinases and ion channels, whereas only the 
remaining 5% were designed for intractable intracellular hosts62. A key factor for the low success 
in the latter group of peptide drugs is the overall poor cell permeability of these compounds. In 
this context, stapled -helical peptides have emerged as an effective solution to this problem, 
since when properly designed, they show significantly improved cell penetration capabilities24-25, 
30. Several reports have investigated in depth the internalization of this class of compounds as well 
as their mechanism of cellular uptake. Thus, Verdine’s laboratory developed an effective 
epifluorescence microscopy assay to evaluate the cell penetration of over 200 FITC-labeled 
peptides derived from several sequences and tethered with different staples that were placed at 
various positions in the parent sequence63. This quantitative study confirmed the substantial 
superior cell penetrating power of stapled peptides versus their linear counterparts, even when 
comparing them to natural unmodified cell penetrating sequences. This work also indicated that 
both the stapling type and the formal charge of the resulting macrocycle are key for peptide 
translocation, while other physical parameters didn’t have a significant effect. The former is 
especially favored by the incorporation of all-hydrocarbon staples and the latter by net positive 
charges below +7 at physiological pH. Interestingly, the correlation between cell penetration and 
net charge observed in this work is not in agreement with other studies carried out with linear 
peptides and mini-proteins, in which a higher net positive charge translates into better 
internalization likely due to higher interaction with the negatively charged phospholipid membrane. 
These researchers also provided mechanistic insights for the cellular uptake of such stapled 
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peptides, which occurred by an endocytosis pathway and through the interaction with sulfated 
proteoglycans located in surface of the cell membrane.  
The Walensky laboratory has also investigated extensively both the biophysical parameters 
impacting the internalization of all-hydrocarbon stapled peptides and their import mechanism. 
Thus, in an early work carried out on leukemia cells, this group showed that BID BH3 stapled 
peptides were internalized through a micropinosomal mechanism followed by pinosomal release19. 
This result was consistent with a later report that used electron microscopy assays to confirm 
vesicular cellular uptake, without plasma membrane disruption64. The latter mechanism has also 
been demonstrated by high resolution fluorescence correlation microscopy studies, performed with 
stapled p53 peptides capable of restoring p53 function by dissociating both p53-HDM2 and p53-
HDMX interactions dose-dependently27. Likewise, an extensive study published by this laboratory 
in 2016 focused on determining the biophysical parameters favoring the cell penetration properties 
of these macrocycles65. This report studied the internalization of a staple-scanning library of FITC-
labeled stapled peptides designed to target BCL-X, an anti-apoptotic transmembrane protein that 
regulates mitochondrial biomolecules involved in programmed cell death mechanisms. The results 
identified the degree of hydrophobicity of the peptide as a major factor for enhanced cellular 
uptake, which is particularly favored when the hydrophobic all-hydrocarbon brace is placed at the 
amphipathic boundary of the peptide binding face. Notably, an excess of hydrophobicity and/or 
net positive charge are also undesired since cyclopeptides with such properties are more prone to 
cause membrane lysis at high concentrations.  
To date most of the comprehensive permeability studies have been carried out with all-
hydrocarbon stapled peptides. It is likely that the rules governing the cell penetrating power of 
such compounds also apply to the internalization of macrocycles bearing other types of staples. 
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This hypothesis has been partially demonstrated by Zigang Li et al. who investigated the impact 
of different stapling architectures on the physicochemical and cell permeability properties of a 
model peptide, targeting the estrogen receptor coactivator66. Notably, the authors observed that 
polar linkers such as lactam or triazole diminished substantially the cellular uptake, whereas 
hydrophobic braces improved significantly cell permeability. Overall, they concluded that 
hydrophobicity correlates well with peptide translocation, in contrast with helical character that 
was not a major factor. More comprehensive studies using other model peptides and staples with 
different chemistries will contribute to a better understanding of the biophysical determinants for 
the effective cellular uptake of stapled peptides.  
1.2.3 Staple Peptide’s Stability to Proteolysis  
The ability of stapled peptides to evade protease degradation is one of the most beneficial 
properties validated for this class of peptidomimetics. Although stapling is typically applied to 
induce a desired bioactive -helical conformation67676767, such conformational restriction also 
limits the ability of enzymes to recognize their natural peptidyl substrate. By “blinding” proteases 
through macrocyclizations or with the incorporation of unnatural building blocks, in vitro 
proteolysis is decreased and serum stability is significantly improved22, 68. This translates into 
enhanced pharmacokinetic properties and thus, into a more favorable drug profile. Indeed, the 
strong resistance of several families of stapled peptides to proteolytic degradation has been 
substantially validated in vitro, by subjecting them to enzymatic reactions using proteases with 
broad substrate specificity such as α-Chymotrypsin, Pepsin and Proteinase K60, 67. Likewise, their 
stability in plasma, liver microsomes and in vivo has also been well-demonstrated69.  All these 
studies have shown that the lifetime of stapled peptides usually ranges from several hours to days, 
far exceeding that of their linear counterparts, which are mostly degraded within minutes. This 
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remarkable resistance to proteolytic degradation has been observed in stapled peptides derived 
from large sequences and in macrocycles tethered by staples of various chemical nature. A 
representative example of the former was reported by Walensky and coworkers who introduced 
two all-hydrocarbon braces via the RCM reaction into a 36-residue long peptide to afford a double-
stapled or “stitched peptide” (SAH-gp41), which effectively targets the HIC-1 fusion apparatus70. 
Notably, this compound showed enhanced stability both in vitro and in vivo and improved oral 
bioavailability, as compared to its linear parent sequence22. As mentioned before, macrocycles 
stapled via methodologies other than RCM reaction also show strong protection to proteases, 
indicating that this feature is not highly dependent on the structure of the brace used for ligation. 
Thus, cyclopeptides containing bis-triazole, vinyl sulfide, bi-aryl or aryl-tryptophan linkers have 
all shown significantly improved stability to protease degradation. 
The ultimate validation of the stability achieved by means of properly introducing a 
stapling linker into a bioactive peptide sequence is given by the development of the first stapled 
peptide drugs entering clinical trials. Aileron Therapeutics, founded in 2005, announced its first 
all-hydrocarbon stapled peptide (ALRN-5281) entering human Phase I trials in 2013, as a potent 
agonist of the growth hormone releasing factor (GRF) currently tested for orphan endocrine 
disorders. The same company has recently developed a second stapled peptide drug, ATSP-7041, 
which targets an intracellular interaction in between MDM2 and MDMX and thus is capable of 
activating the function of the human tumor suppressor transcription factor p53 in vitro and in 
vivo29,71.   
1.2.4 Stapled Peptides: Improved Target Binding Affinity and Diversity of Binding Strategies 
The potential of stapled peptides as effective chemical modulators of intracellular protein-
protein interactions was first demonstrated by Walensky et al. in 200419. In this breakthrough 
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discovery, these researchers demonstrated that introducing all-hydrocarbon braces into unfolded 
BH3 peptides induced -helical conformations in such sequences, which showed helicities of up 
to 90% in solution. Moreover, the resulting all-hydrocarbon stapled peptides were remarkably 
resistant to proteolytic degradation in both in vitro and in vivo studies, and in addition, exhibited 
in vitro nanomolar binding affinity for their BCL-2 family targets. These cell penetrant 
peptidomimetics, referred to as “stabilized” alpha-helix of BCL-2 domains (or SAHBs), were also 
able to trigger cellular stress and apoptosis in vivo.  
After this original report, a large number of research groups have applied the RCM 
technology, and also most of the newly-developed stapling approaches, to generate a wide array 
of potent inhibitors of intracellular and extracellular PPIs. These modulators of protein function 
have shown potential applications in several diseases including cancer, metabolic and infectious 
diseases as well as neurological disorders (Table 2). Thus, for example, the Walensky laboratory 
has identified a series of BH3 mimetics that directly bind to MCL-1, and drive cancer cells to 
caspase-dependent apoptosis72. Other critical cancer-related mechanisms that have been 
successfully targeted by all-hydrocarbon stapled peptides include the Wnt/Beta-catenin and the 
NOTCH signaling pathways73-74. Likewise, Pellegrini et al. have used the two-component Azide-
yne stapling reaction to develop a potent inhibitor of the Ctf4-DNA Polymerase α interaction28. 
Ctf4/AND-1, a core component of the replisome progression complex, is an adaptor protein that 
bridges the helicase with Polymerase α complexes, and thus plays a key role in DNA replication, 
repairs and chromosome segregation. Despite its biological relevance, Ctf4 has been an elusive 
target possibly because it lacks a well-defined active site, being thus unfit for small molecule 
design. Notably, these investigators have successfully developed an (i, i+6) macrocycle (Sld5) that 
shows sub-micromolar binding affinity to Ctf4. Sld5 is capable of effectively displacing the Ctf4 
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partner, DNA polymerase, and thus acts as a potent DNA-damaging cancer therapeutic agent. It is 
worth noting that although this cyclopeptide shows poor cellular uptake, it is expected that further 
modifications to the topology of the tethering linker will contribute to improve its overall cell 
permeability. 
The incorporation of a “staple” into a linear peptide sequence is now a proven and powerful 
tool for inducing bioactive α-helical conformations, and thus for the rational design of targeted 
peptide therapeutics. Interestingly, the spacer used for ligation can also provide additional binding 
benefits that extend beyond precise structural mimicry. This idea has been introduced by Popowicz 
and coworkers73, 75 who reported an X-ray structure of a stapled p53 peptide, SAH-p53-8, in 
complex with its protein target MDM273, 75. This structural analysis revealed that the hydrocarbon 
brace of SAH-p53-8 contributes to the binding energy by establishing hydrophobic interactions 
with some residues in the protein surface, thus expanding the role of the staple from a purely 
structural stabilizer or permeability enhancer, to an element that can be exploited for increased 
binding affinity.  
Overall, the progress achieved in the stapled peptide technology has allowed the 
identification of novel therapeutic agents targeting intractable protein surfaces, inadequate to be 
tackled by small molecule ligands.  Such success is illustrated by the discovery of the first staple 
peptides entering human clinical trials. ALRN-6924, a second-generation macrocycle developed 
by Aileron Therapeutics, effectively disrupts the interaction between the p53 tumor suppression 
protein and both the murine double minute 2 (MDM2) and murine double minute X (MDMX) 
proteins, and is currently being tested in patients with peripheral T-cell lymphoma (PTCL), acute 
myeloid leukemia (AML) and myelodysplastic syndrome (MDS)71. The potential success of this 
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compound, and of others currently in development, could certainly transform the future of PPI’s 
inhibitors development.  
Table 1.2 Applications of the Stapled Peptide Technology in a Variety of Human Diseases 
 
Disease Protein Target Stapling Method Reference 
       Cancer 
BCL-2 Proteins BAK/SAHB/BAX RCM Walensky et al.
19, 70
 
MCL-2/BH3/BAX RCM Walensky et al.
67
  
BAK/BID-BH3 RCM Moldoveneau et 
al.76  
MDM2/MDMX p53/(HDM2/MDM2) RCM Bautista et al.
77
 
p53/(MDM2/MDMX) RCM Chang et al.
26
 
p53/MDM2 RCM Popowicz et al.
75
 
p53/MDM2 Azide-yne  Spring et al.78  
p53/MDM2 Thiol-ene Chou et al.45 
NOTCH SAHM1/NOTCH RCM Moellering et al.
73
 
BETA-CATENIN BCL-9/βCATENIN RCM Ye Wu et al.74 
IRIS IRS1/p110α RCM Hao, Y. et al.79 
PRC2 EED/EZH2 RCM Kim W et al.
80
 
RAB25 RAB25/FIP RCM Moellering et al.
81
 
Programed cell death XIAP & cIAPs Azide-yne Terrett et al.
68
 
Wnt Signaling PARP/Wnt Azide-yne Spring, et al.
58
 
Wnt Signaling TNKS/Wnt Azide-yne Spring, et al.58 
DNA Replication SLD5/CTF4 Azide-yne Spring et al.
28
 
Receptor-coactivator ER-coactivator Thiol-yne Zigang et al.
66
 
   Infectious Diseases 
HIV-1: Gag, integrase HIV-1 CA protein/ NYAD-1 RCM Long, Y. et al. 23 
GP41 GP41 six-helix bundle RCM Walensky et al. 
22
 
HCV-E2 HCV-E2/ CD81 RCM Cui et al. 
82
 
         Diabetes 
Insulin releasement GLP-1 Dithiol bisalkylation Weijun Shen et 
al.
83
 
      Metabolism 
ABCA1 transporter ABCA1 RCM Sviridov et al. 
84
 
 Estrogen Receptors 
 Estrogen receptor RCM Irving et al. 85 
 Estrogen receptor  Thiol-yne Zigang et al. 66 
Neurological Disorders 
NMDA receptor Conantokins 
mimetic/NMDAR 
RCM Gajewiak et al 
86
 
Neurotensin receptor Neurotensin receptor C-C bond activation 
(Suzuki) 
Jieping Zhu et al. 
87
 
Neurotransmitter at 
synapses 
Dipeptidyl peptidase III 
ATP-activated human P2X3 
receptor 
C-H bond activation 
(Pd(II)) 
Lavilla et al.
 60
 
   Others   
Autophagy Human Beclin 1 Dithiol alkylation Kritzer et al 
36
 
Neurotoxic rAps III/Na+ Channels Disulfide Linkage King et al. 88 
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1.3 Long Range Macrocyclization Methodologies 
Long-range macrocyclization strategies are one of the earliest methods used to successfully 
modify peptide’s secondary structures (Figure 1.3.1). Macrocyclization differs from cyclization 
based on the relative length of residues to be joined or linked, relative to the length of the peptide. 
Thus, in general terms 12 or more membered rings are considered “macrocycles”.  Due to their 
large size, and thus the ability to interact with extended surfaces, macrocyclic peptides are also 
ideal candidates for disrupting protein-protein interactions. Indeed, over the last several decades, 
macrocyclizations have attracted a great deal of attention by medicinal chemists76. 
Figure 1.3.1 Structural representation of long range macrocyclization. 
 
The strategies used for macrocyclizing peptides are diverse and escape any simple 
classification scheme77. Most broadly, methods are categorized based on what functional regions 
of the peptide are involved in the eventual linkage. The possibilities include head-to-tail, head/tail-
to-side chain, or side chain-to-side chain macrocyclic strategies. Within these broad descriptions 
of overall architecture, one can subcategorize based on the reaction pathway or the class of the 
resulting product. Several reactions have been applied to achieve macrocyclizations. The most 
popular ones include lactamization, lactonization, the RCM reaction, transition metal-catalyzed 
cross couplings and the one-pot azide-alkyne click chemistry cycloaddition76,78-80.  Lactamization 
is likely the most frequently utilized, since it can exploit the reactivity between head and tail, basic 
side chains and tail, acidic side chains and head, or basic and acidic side chains. Evidently,  
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lactamization can be applied to nearly every architectural class, largely due to the diversity of 
amino acid side chains.  
When combined with the use of non-natural amino acids, orthogonal protecting group 
strategies, and biosynthetic pathways, the methods and potential products of macrocyclization 
increase in diversity. Thus, in addition to standard reactions above-cited, other chemistries applied 
to macrocyclizing peptides include oxadiazole grafting81, sulfur-mediated cyclizations77, 82, 
isocyanides and other multicomponent reactions77, 82, and intein-catalyzed S/N acyl transfer83. All 
these approaches have been extensively reviewed and include both internal modifications to the 
linear peptide, and external template modifications76, 77, 82. It is worth noting that for any 
macrocyclization, it is crucial to control the factors favoring such transformation over other 
intermolecular reaction pathways. One highly effective strategy to achieve such a goal is by 
reducing the concentration of the reacting species, i.e, to perform reactions at high dilution and/or 
to control the rate of addition of either the substrate or reagents. Similarly, through conformational 
control of the linear precursor it is possible to lower the entropy of the substrate, and thus induce 
a “turned conformer” in which both reacting ends are brought in close spatial proximity. These 
strategies are also discussed in the previously mentioned reviews.  
 
1.3.1 Cell Permeability of Macrocyclic Peptides 
Cell permeability remains a major challenge for macrocyclic peptides. While they have 
been demonstrated as highly effective and specific modulators of many extracellular PPIs, few 
macrocyclic peptides demonstrate high cell permeability. A recent review by Walport and 
colleagues discusses potential paths forward for transforming macrocyclic peptides into cell 
permeable molecules84. Unlike -helices, where the characteristic secondary structure allows for 
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the internalization of hydrogen bond-participating side chains, the secondary structures assumed 
by macrocyclic peptides do not necessarily possess this same helpful characteristic. Instead, the 
method of using N-methylated residues is frequently employed to reduce the number of hydrogen 
bond donors and increase overall hydrophobicity of macrocyclic peptides to increase cell 
permeability85 and bioavailability85-86. 
A novel alternative strategy for conferring cell permeability to macrocyclic peptides, 
involves coupling them with known cell permeable peptides (CPPs). Using this method, Trinh and 
co-workers tested the impact of incorporating cyclo(FΦRRRRQ) (cFΦR4, where Φ is L-2-
naphthylalanine), a CPP with known cell internalization properties, into macrocycles designed to 
target K-Ras, an oncogene that plays a key role in cell differentiation and apoptosis87. Indeed, this 
strategy yielded cell-penetrating bicyclic peptides capable of inducing apoptosis in cancer cells, 
thus validating the applicability of this approach. The CPP used in this study is thought to gain 
intracellular access by binding directly to phospholipids of the cellular membrane and internalizing 
via endocytosis88. 
 
1.3.2 Macrocyclic Peptides as inhibitors of PPIs 
Macrocyclic peptides have been effective at targeting PPIs involved in a variety of 
biological pathways, including cancer, infectious and autoimmune diseases and regenerative 
medicine. Some representative applications of such inhibitors are presented in Table 1.3.  
An elegant and highly novel example showing the potential of this class of compounds 
have been recently published by Ito and co-workers89. Notably, the authors have developed dimeric 
macrocyclic peptides capable of inducing dimerization of the hepatocyte growth factor (HGF) 
receptor, also known as Met or c-Met, and thus activate downstream Met signaling cascades. These 
compounds underwent a first macrocyclization by a head-to tail thioether-linkage forming reaction, 
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between an N-terminal chloroacetyl group and thiol functionality. Dimerization of the monomers 
was next achieved by coupling C-terminal cysteine residues with bis-maleimide linkers of different 
lengths. The resulting dimeric macrocycles were capable of promoting cellular responses such as 
migration, proliferation and branching morphogenesis at low nanomolar concentration. This 
example demonstrates the unique cellular mechanisms accessible to macrocyclic peptide 
therapeutics. 
Table 1.3 Representative examples of macrocyclic peptides disrupting biologically relevant PPIs. 
 
1.4 Peptidomimetic Molecules for Therapeutic Development: Significance 
Unquestionably, the methodologies applied to peptide stabilization have made a significant 
contribution to therapeutic development. In particular, the discovery of the stapled peptide 
Disease / Pathway Protein Target Macrocyclization Method Reference 
Leukemia MM401-WDR5 RCM Dou, Y. et al.92  
Leukemia MM589-WDR5 Lactamization (Internal) Wang, S. et al.
93
  
Ebola VP24-KPNA5 Thioether Suga, H. et al.102 
Wound healing Met-hHGF Thioether Suga, H. et al.
103
 
Immune response 
Cancer, Organogenesis 
PB1m6-Sema4D Thioether Suga, H. et al.
104
 
Phosphorylation AKT2-Pakti L1 Thioether Suga, H. et al.105 
Cancer Ras-Cyclorasin 9A5 Lactamization (Internal) Pei, D. et al.
106
 
Phosphorylation 
Cis−trans isomerization 
PTP1B 
Pin1 
lactamization Pei, D. et al.
107
 
Identification and 
isolation of potent 
Streptavidin binder 
Streptavidin 
Intein-catalyzed S, N acyl 
transfer 
Fasan, R. et al.
96
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technology by Verdine and colleagues in 2000 has triggered an exponential and growing number 
of relevant publications in the field. Considerable progress has been made in the synthetic 
approaches allowing access to these compounds. Likewise, the data generated so far have 
enhanced our overall understanding of basic rational design principles, mechanisms of cellular 
uptake and factors impacting the pharmacokinetic properties of these macrocycles. More 
importantly, this technology has allowed the identification of potent inhibitors of biologically 
relevant PPIs that were inaccessible using traditional medicinal chemistry approaches. Such 
remarkable advances, achieved in a relatively short period of time, have led to the development of 
the first stapled peptides entering human phase 1/2 clinical trials by Aileron Therapeutics, the 
leading company in the field, whereas several others compounds are currently in the pipeline. 
Altogether, these studies demonstrate the tremendous potential of peptidomimetic molecules for 
the generation of novel and effective therapies to treat incurable human diseases. 
In this regard, the work described in these doctoral thesis focuses, first, on developing a 
new and an efficient synthetic methodology for the chemoselective solid phase synthesis of single- 
and double-turn bis-thioether stapled peptides. The scope of this approach is demonstrated by 
synthesizing macrocycles derived from several sequences, validating its compatibility with 
different amino acids and SPPS. This method allows access to cyclopeptides tethered by all-
hydrocarbon linkers of different lengths, avoiding the use of unnatural amino acids and expensive 
catalysts. Moreover, it affords macrocycles with marked resistance to proteolytic degradation. We 
expect this feature to result in an improved pharmacokinetic profile that makes this family of 
compounds suitable for use in biological studies. 
Furthermore, we also present the application of our synthetic approach to generate stapled 
peptides that effectively disrupt biologically relevant intracellular PPIs. More specifically, we 
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describe three families of stapled peptides as allosteric inhibitors of PRC2 methyltransferase 
activity. Compared to their linear counterparts, these compounds showed enhanced -helical 
structure and inhibition of target function. Our lead cyclopeptides were found to be potent 
inhibitors of H3K27 trimethylation in both in vitro and cellular assays, demonstrating their cell 
permeability and activity in physiological conditions. Inhibition of PRC2 catalytic activity by these 
compounds was correlated with a marked dose-dependent antiproliferative effect in metastatic 
Cakis-1 cells. Remarkably, in these experiments our three lead compounds were virtually as potent 
as GSK126, an EZH2-SET domain inhibitor currently in clinical development. The structure of 
our novel stapled peptides highlight the relevance of our crosslinking reaction, since such 
macrocycles are tethered by a three-methylene hydrocarbon brace that can only be efficiently 
introduced using our solid phase synthetic approach. The allosteric PRC2 inhibitors described 
herein could be of great value to address the resistance profiles found after extended dosing with 
the PRC2 inhibitors currently undergoing clinical trials, all of which target the catalytic SET 
domain of EZH2. 
1.5 Acronyms and Abbreviations 
All the abbreviations used for amino acids and peptides follow the rules of the IUPAC-
IUB Commission of Biochemical Nomenclature in J. Biol. Chem. 247, 977-983 (1982). In addition, 
the following abbreviations are used: SPPS: Solid Phase Peptide Synthesis, DMF: N,N-
dimethylformamide, DCM: dichloromethane, Fmoc: 9H-fluorenylmethyloxycarbonyl, DIEA: 
N,N-diisopropylethylamine, PyBOP: (benzotriazol-1-yloxy)tripyrrolidinophosphonium 
hexafluorophosphate, TFA: trifluoroacetic acid, Oxyma: Ethyl cyano(hydroxyimino)acetate, NaI: 
Sodium Iodide, TCEP: Tris(2-carboxyethyl)phosphine hydrochloride, Boc: tert-Butyloxycarbonyl, 
Trt: trityl, Pbf: 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl, Mmt: 4-methoxytrityl, EDT: 
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1,2-ethanedithiol, Et2O: diethyl ether, TFMSA: triflic acid, trifluoromethanesulfonic acid, TIS: 
triisopropylsilane, ACN: acetonitrile, FA: formic Acid, HPLC-MS: high performance liquid 
chromatography mass spectrometry, HRMS(ESI): high-resolution mass spectrometry 
(electrospray ionization), RP-HPLC; reversed phase-high performance liquid 
chromatography, BAK: BCL-2 antagonist/killer, BAX: BCL-2 associate X, BCL-2: B-cell 
lymphoma 2, BCL-9: B cell lymphoma 9, BH3: BCL-2 homology domain 3, FP: Fluorescent 
polymerization, MCL-1: myeloid leukemia cell differentiation protein, MOMP: Mitochondrial 
outer membrane permeabilization 
PARPs: Poly (ADP-ribose) polymerases, TNKS: Tankyrase proteins, SAH-gp41: Stabilized α-
helix of GP4 
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Chapter II. A Solid Phase Approach to Accessing 
Bisthioether Stapled Peptides 
2.1 Introduction 
Several synthetic approaches yielding stapled peptides have been developed in the last few 
years, mostly in solution phase, each one having its own advantages and drawbacks.90 Thus peptide 
stapling can be achieved today with a variety of spacers, however, the number of methods 
affording macrocycles tethered by all-hydrocarbon spacers remains scarce. Given the great 
promise of this class of compounds as therapeutics and their favorable pharmacokinetic properties, 
new protocols granting easy access to them continue to be of great interest.  In this chapter, we 
report the development of an efficient solid phase method for the chemoselective ligation of 
cysteine residues applicable to the preparation of single-, double-turn and double-stapled 
macrocycles. This approach allows for ligation with all-hydrocarbon linkers of various lengths, 
avoiding the use of unnatural amino acids and expensive catalysts, and affords cyclopeptides with 
remarkable resistance to proteolytic degradation.  
2.2 Optimization of the Stapling Reaction.  
Our goal was to develop a solid phase approach that can be applicable to both hydrophilic 
and poorly soluble hydrophobic peptides. In addition, in contrast to the currently available cysteine 
stapling methods, we envisioned that such protocol could also allow the chemoselective ligation 
of sequences containing several cysteine residues and to prepare macrocycles containing multiple 
bisthioether staples.  
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For our initial optimization studies were chose a 10-mer sequence containing two cysteines 
at positions i and i+4. (Scheme 2.2.1). The peptide was elongated on a low substituted resin to 
avoid undesired intermolecular crosslinking during the ligation step. To allow selective 
deprotection on beads, both Cys were orthogonally protected with 4-methoxytrityl (Mmt). We first 
attempted the cyclization using the conditions reported for a similar reaction in solution phase, 
however, in our case it only afforded small amounts of the desired cyclic peptide, mixed with 
unreacted linear precursor(-SH, -SH) and the disulfide-bridged (S-S) macrocycle (Table 2.1, Entry 
1).43  
To push the reaction toward the formation of the stapled peptide, we then designed a series 
of 30 combinatorial experiments, with variation of one parameter at a time, and tested the use of 
different solvents, non-nucleophilic organic and inorganic bases, microwave activation and length 
of reaction time. We also explored including sodium iodide, to increase the electrophilicity of the 
dibromoalkane by inducing in situ trans-halogenation, and TCEP to prevent the disulfide oxidation 
(Table 2.1). From these experiments, we identified optimal conditions (DIEA 35 eq., TCEP 0.5 
eq., linker 3.5 eq. microwave 125 oC, 2 min) that led to 98% conversion to the desired bisthioether 
cyclopeptide, in high purity, as determined by both LC/MS and HPLC analysis (Table 2.1, Entry 
7J). Subsequently, the reaction was scaled up. However, further efforts to complete peptide 
elongation to a 19-mer proved unsuccessful, primarily due to inefficient amino acid couplings after 
cyclization.   
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Scheme 2.2.1 Synthetic scheme initially designed to study the stapling reaction on a 10mer linear Peptide. 
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Table 2.1 Preliminary optimization results of solid phase cyclization using a 10 mer peptide 
(Scheme 2.1): Resin-ISLISCSLSC-Alloc (Optimal results obtained with conditions described in 
entry 7J)  
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We then study the reverse approach, i.e, elongating the peptide first and performing the 
stapling reaction thereafter. The full sequence was assembled using pseudoproline dipeptides to 
avoid potential aggregation problems that may have caused the incomplete couplings observed 
before. 91 Subsequent Cys-Mmt deprotection and stapling of this substrate, using the previously 
optimized conditions, afforded the desired bis-thioether stapled peptide in high overall purity as 
discussed in details in the following section. 
2.3  Solid Phase Synthesis of Single-Turn Stapled Peptides (i, i+4).  
Single-turn peptide stapling was investigated using dibromoalkyl electrophiles containing 
three different hydrocarbon chains and following the synthetic scheme depicted below (Scheme 
2.3.1). The solid phase synthesis of the Cys-mutated linear precursor 1 was accomplished using 
pseudroproline dipeptides and afforded a highly pure crude material (Figure S2.1, S2.2).  
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Scheme 2.3.1 Solid phase synthesis of single-turn (i, i+4) stapled peptides bearing all-hydrocarbon 
linkers of different lengths.  
 
 
  
AcNH 
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Next, we carried out Cys-Mmt deprotection, which was accurately quantitated by means 
of a “maleimide test” developed in our laboratory (Scheme 2.3.2). Subsequent cyclization with 
1,3-dibromopropane yielded only the expected stapled peptide with an overall purity for the total 
synthesis greater than 80 % (Table 2.2, Scheme 2.3.1, Figure S2.1 and S2.2). This reaction can be 
scaled up to produce 75% pure stapled peptide from 5 g of resin.  
 
Scheme 2.3.2 Maleimide test developed to assess the efficiency of the Mmt-deprotection 
reaction. Since bulky protecting groups in the vicinity of Cys-Mmt could cause incomplete 
deprotection despite the sensitivity of Mmt to acid media, we developed conditions for 
quantitatively assessing the efficiency of Mmt deprotection. Free thiols generated after 
deprotection, are covalently blocked through a well-known thiol-maleimide addition step. 
Cleavage of an aliquot of the reacted peptide, and LC/MS analysis allow to unequivocally assign 
fully deprotected products, partially or non-deprotected sequences, as well as mixtures containing 
all of them. 
1) N-methyl-maleimide (5eq)
    DIEA (5eq), DMF
2) TFA cleavage
S
S
N
N
O
O
O
O
S
SH
Mmt
Me
Me
SH
SH
S
SH
NO
O
Me
S
S
Mmt
Mmt 2% TFA 
10% TIS
in DCM
S
SH
Mmt
Ellman’s Reagent (DTNB)
If there is Incomplete Deprotection
(Positive, no detection of 
protected thiols)
Cleavage will  remove the 
remaining Mmt groups
(Incomplete deprotection 
 wont be detect d)
Solution
2% TFA 
10% TIS
in DCM
Fully Deprotected
S
S
Mmt
Mmt
SH
SH
1) N-methyl-maleimide (5eq)
    DIEA (5eq), DMF
2) TFA cleavage
1) N-methyl-maleimide (5eq)
    DIEA (5eq), DMF
2) TFA cleavage
S
S
Mmt
Mmt
Partial Deprotection No Deprotection
LC/,MS Analysis of the crude after cleavage allows to unequivocally determine the extent of the deprotection reaction
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Table 2.2 Synthesis of single- (i,i+4), double-turn (i,i+7) and double-stapled peptides  
PP= (psiMe, Mepro), C3: 1,3-dibromopropane, C4: 1,4-dibromobutane, C5: 1,5-dibromopentane, C4ene: trans-1,4-
dibromobutane, C6: 1,6-dibromohexane, C7: 1,7-dibromoheptane, C8: 1,8-dibromooctane. A: DIEA (35 eq), TCEP 
(0.5 eq), NaI (17.5 eq), MW, 125oC, 2 min.  B: DIEA (35 eq), TCEP (0.5 eq), NaI (17.5 eq), room temp., 12h.     C: 
DIEA (35 eq), TCEP (3 eq), NaI (100 eq), MW, 125oC, 2 min. HPLC and HRMS chromatograms of all crude reaction 
mixtures are provided in 1.7.2 (Figures 5.1-5.8). The methods used for calculating conversion and purity by HPLC 
and HRMS are described below, in the General Experimental Information section of this document. 
 
HS
SH
Reaction conditions:
TCEP, Base
NaI, Dibromolinker
DMF, MW
S4d-f (i, i+4, +Cys)
SS
2-5, S4d-f, 12
n
(n = 0, 1, 2)
X SS X
n
(n = 3, 4, 5)
2-5 (i, i+4)
SS
X
SS
X
HS SS
X
12 [2 x (i, i+4)]
X =
7-9
7-9 (i, i+7)
 
Entry Product Linker 
(X) 
(eq) 
Rxn 
 
Conversion 
To Cyclic  
(%, HPLC) 
% Purity 
Cyclic 
(HPLC) 
% Purity 
Cyclic 
(MS) 
% Linear 
(HPLC) 
% Dha 
(HPLC) 
         10mer:  Resin-ILS(Trt)IL[CS(Trt)LS(Trt)C]X-Alloc (95%, HPLC) 
I S1C C3 (3.5) A          98   85         83                        -  - 
(i,i+4)        1          19mer:  Resin-ILS(PP)IL[CS(tBu)LS(tBu)C]XT(PP)VK(Boc)K(Boc)S(PP)AE(tBu)FI-Ac (92%,HPLC) 
II 2 C3 (3.5) A 84 80 89 - - 
III 2 C3 (3.5) B 88 84 80 6 - 
IV 3 C4 (3.5) A 52 49 43 4 29 
V 4 C5 (3.5) A 85 81 78 - 13 
VI 5 C4ene (5) A 59 56 65 14 - 
(i,i+7)        6          19mer:  Resin-IL[CILN(tBu)S(PP)LS(Trt)C]XT(tBu)VK(Boc)K(Boc)S(PP)AE(tBu)FI-Ac (94%, HPLC) 
VII 7 C7(3.5) A     48+20(S-S)           48    50 18 - 
VIII 7 C7 (20) C 99 95 80 - - 
IX 8 C6 (20) C 99 94 89 - - 
X 9 C8 (20) C 64 70 57 27 - 
(i,i+4,+Cys) S2a    13mer:  Resin-LLD(tBu)K(Boc)[CLR(Pbf)S(Trt)C]XC(tBu)K(Boc)N(Trt)Q(Trt)-Ac (92%, HPLC) 
XI   10 C3 (3.5) A 90 91 85 - - 
XII   11 C4 (3.5) A 61 56 55 - 32 
XIII   12 C5 (3.5) A 70 68 65 - 19 
[2 x(i,i+4)]  13                       19mer:  Resin-N(Trt)Q(Trt)PV[CE(tBu)ALC]XS(PP)L[CS(PP)AIC]XD(tBu)VT(tBu)-Ac 
XIV      14 C3, C3 (20) A 85 68 72 - - 
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We also applied this method for the cyclization with 1,4-dibromobutane and 1,5-
dibromopentane. These reactions also led to the expected bisthioether macrocycles, however, 
HRMS analysis of the reaction crudes also showed a significant amount of a side product of smaller 
molecular mass in both reactions (Figure S2.1 and S2.2). The structure of this compound was 
assigned to a bis-dehydroalanine substituted peptide (Scheme 2.3.3). Conversion of cysteine to 
dehydroalanine (Dha), by means of a cyclo-bis-alkylation-elimination mechanism, has been 
reported to be particularly effective when 1,4-diodo or 1,4-dibromobutane are used as 
electrophiles.92 This is likely due to the stability of the cyclic S-bialkylated sulfonium intermediate 
needed for the elimination step. 
 
Scheme 2.3.3 Mechanism for the formation of bis-dehydroalanine substituted peptides as a side 
product in the direct alkylation of cysteine residues. Cysteine conversion to dehydroalanines (Dha) 
was recently reported by Chalker et al. to take place through a bis-alkylation-elimination 
mechanism, which is particularly effective when using 1,4-diodo or 1,4-dibromobutane as 
electrophiles. 
To avoid this unwanted transformation, we used trans-1,4-dibromo-2-butene as 
electrophile since this rigid substrate would not form the key cyclic sulfonium intermediate. As 
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expected, this reaction only afforded the desired bis-thioether stapled peptide, thus confirming the 
previous structural assignment (Table 2.2, Figure S2.1 and S2.2).  
2.4 Solid Phase Synthesis (SPPS) of Double-Turn Stapled Peptides (i, i+7)  
We expanded our method to the preparation of double-turn stapled peptides (i, i+7) over 
the same 19-mer sequence, containing cysteines at positions 10 and 17 respectively (Scheme 
2.4.1). The synthesis of the linear precursor included the use of pseudoproline dipeptides and 
yielded a highly pure crude material (Figure S2.3 and S2.4). After quantitative Cys-Mmt 
deprotection, as determined by our maleimide test, we proceed to cyclization using 1,7-
dibromoheptane as electrophile under the previously optimized conditions. 
The cyclization with 1,7-dibromoheptane under the previously optimized conditions 
afforded the expected macrocycle, but also the linear unreacted substrate and the disulfide oxidized 
product (Table 2.2). This result was not surprising since macrocyclization to form this larger ring 
is likely to be more challenging due to an increase in the conformational entropy of both the linear 
peptide (both thiols are further apart) and the electrophile (longer hydrocarbon chain). A second 
round of optimization was then conducted to improve efficiency of this stapling reaction. From 
those studies, we concluded that increasing the number of equivalents of both the electrophile and 
TCEP results in a 99% conversion to the desired cyclic product (Figure S2.3 and S2.4). The same 
reaction conditions allowed the successful preparation of (i, i+7) stapled peptides bearing all-
hydrocarbon linkers with six and eight methylene groups (Table 2.2, Figure S2.3 and S2.4).  
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Scheme 2.4.1 Solid phase synthesis of single-turn (i, i+7) stapled peptides bearing all-hydrocarbon 
linkers of different lengths. Full characterization and experimental details are given in the 
Appendixes. 
 
2.5 Solid Phase Synthesis of Single-Turn Stapled Peptides with Additional Cysteines in the 
Sequence (i, i+4, +Cys). 
We further extended our approach to the cyclization of peptides containing additional 
cysteine(s) residues in the sequence. The chemoselective ligation of such peptides requires 
orthogonal protection of the extra thiol(s), to avoid undesired crosslinking with the Cys used for 
ligation. Two orthogonal protecting groups were studied, tert-butylthio (S-tBu) and tert-Butyl 
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(tBu), since they are both compatible with Fmoc and Mmt chemistries and are commercially 
available.5,6 Macrocyclization was carried out on a 13-mer linear precursor containing a total of 
three cysteines, two Mmt-protected used for stapling, and the third one blocked as either S-tBu or 
tBu (Scheme 2.5.1). After selective Mmt-deprotection and quantitative cyclization, we proceed to 
investigate the reaction conditions for the removal of both orthogonal protecting groups. Cys-StBu 
was effectively deprotected using a mild reducing agent in basic conditions93. In contrast, Cys-tBu 
removal was more effective when performed in solution, after the stapled peptide had been cleaved 
off the resin 94. Overall, both protocols yielded the corresponding selectively stapled macrocycle 
in good yields and high purity (Figures S2.5 and S2.6). However, we concluded that orthogonal 
protection with Cys-tBu is preferred due to shorter reaction times and overall simplicity of the 
reaction (Table 2, Entry XI-XIII).     
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Scheme 2.5.1 Synthetic scheme for the preparation of single-turn stapled peptides containing an 
additional cysteine residue in the sequence (i, i+4, +Cys). 
 
2.6 Solid Phase Synthesis of Double Stapled Peptides [2 x (i, i+4)].  
Having optimized the use of orthogonal-cysteine protection in our synthetic method, next 
we explored its feasibility for the chemoselective preparation of “double-stapled” peptides. These 
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studies were carried out with a different 19-mer sequence, containing two pairs of cysteine 
orthogonally protected as Cys-StBu and Cys-Mmt (Scheme 2.6.1). The total synthesis included (1) 
elongation of the linear precursor (2) Cys-StBu deprotection (3) incorporation of first peptide 
staple, (4) Cys-Mmt deprotection and (5) incorporation of second peptide staple. Both Cys 
deprotection steps were monitored by our maleimide test (Scheme 2.3.2). The tethering steps were 
monitored by LC/MS, after cleaving an aliquot of the ligated peptidyl resin. Our synthetic 
procedure allowed the chemoselective preparation of a double stapled peptide, in high overall 
purities (Table 2, Entry XIV, Figures S2.7 and S2.8). 
Scheme 2.6.1 Synthetic scheme for the chemoselective preparation of double-turn stapled [2 x (i, i+4)]. 
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2.7 Conclusion 
In summary, we report a versatile synthetic method for the chemoselective preparation of 
all-hydrocarbon bis-thioether stapled peptides on solid phase, which allows access to single (i+4) 
and double (i+7) turn tethered peptides, as well as to double stapled peptides. Although the latter 
class of compounds has been prepared using the bis-RCM reaction, our protocol is the only 
cysteine-crosslinking method that allows for the incorporation of two hydrocarbon braces of any 
length chemoselectively at any position of the sequence. Our synthetic method affords staple 
peptides bearing all-hydrocarbon linkers of different lengths, an unprecedented feature for any of 
the reported stapling techniques. In addition, it avoids the use of unnatural amino acids and 
expensive catalysts, which makes it affordable and easier to be scaled up. The latter remains a 
concern for the current methods, particularly given the potential application of these class of 
compounds in clinical studies. We demonstrated the scope of this approach by synthesizing 
cyclopeptides derived from several peptide sequences and stapled at various positions, which also 
validates its compatibility with different amino acids and SPPS. This synthetic methodology 
affords macrocyclic peptides with marked resistance to proteolytic degradation, and thus improved 
pharmacokinetic profile, making them suitable to be used in biological studies. 
2.8 Experimental Section 
2.8.1  Acronyms and Abbreviations 
All the abbreviations used for amino acids and peptides follow the rules of the IUPAC-
IUB Commission of Biochemical Nomenclature in J. Biol. Chem. 247, 977-983 (1982). In addition, 
the following abbreviations are used: SPPS: Solid Phase Peptide Synthesis, DMF: N,N-
dimethylformamide, DCM: dichloromethane, Fmoc: 9H-fluorenylmethyloxycarbonyl, DIEA: 
N,N-diisopropylethylamine, PyBOP: (benzotriazol-1-yloxy)tripyrrolidinophosphonium 
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hexafluorophosphate, TFA: trifluoroacetic acid, Oxyma: Ethyl cyano(hydroxyimino)acetate, NaI: 
Sodium Iodide, TCEP: Tris(2-carboxyethyl)phosphine hydrochloride, Boc: tert-Butyloxycarbonyl, 
Trt: trityl, Pbf: 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl, Mmt: 4-methoxytrityl, EDT: 
1,2-ethanedithiol, Et2O: diethyl ether, TFMSA: triflic acid, trifluoromethanesulfonic acid, TIS: 
triisopropylsilane, ACN: acetonitrile, FA: formic Acid, HPLC-MS: high performance liquid 
chromatography mass spectrometry, HRMS(ESI): high-resolution mass spectrometry 
(electrospray ionization), RP-HPLC; reversed phase-high performance liquid 
chromatography, BAK: BCL-2 antagonist/killer, BAX: BCL-2 associate X, BCL-2: B-cell 
lymphoma 2, BCL-9: B cell lymphoma 9, BH3: BCL-2 homology domain 3, FP: Fluorescent 
polymerization, MCL-1: myeloid leukemia cell differentiation protein, MOMP: Mitochondrial 
outer membrane permeabilization 
PARPs: Poly (ADP-ribose) polymerases, TNKS: Tankyrase proteins, SAH-gp41: 
Stabilized α-helix of GP4 
2.8.2 General experimental information 
Microwave reactions were carried out in a Biotage Initiator+ microwave reactor, featured 
with an infrared temperature sensor, and automatic power adjustment to keep the reaction 
temperature constant throughout the entire reaction time. The reactions were performed in sodium 
free glass vials, sealed with a cap equipped with a rubber septum, and under magnetic stirring 
(stirring rate: 300 rpm). Cooling is performed automatically using compressed air, after the 
reaction time ends. 
Reactions were monitored by both HPLC and HPLC-MS.  
- HPLC Characterization. HPLC chromatograms were obtained using an Agilent 1200 instrument 
equipped with a pump, degasser, an autosampler, a diode array detector and automatic collector. 
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Samples were run at four different wavelengths (220 nm, 254 nm, 280 nm and 590 nm), in an 
Eclipse XDB-C18 5 µm column, using as solvents: Solvent A: H2O:CH3CN:TFA (95:5:0.1%); 
Solvent B: CH3CN:H2O:TFA (95:5:0.087%), and either of the following methods:  
 Method 1: Flow rate: 1.0 mL/min., Gradient 10-40% of B in 25min 
 Method 2: Flow rate: 1.0 mL/min., Gradient 15-65% of B in 25min 
 Method 3: Flow rate: 1.0 mL/min., Gradient 35-85% of B in 25min 
 Method 4: Flow rate: 1.0 mL/min., Gradient 10-99% of B in 25min 
- HPLC-MS Characterization. Samples were first injected into an HPLC (Agilent 1200) equipped 
with a pump, degasser, an autosampler and a diode array detector. The flow from the column was 
directed into the Mass Spectrometer (TOF, Agilent 6220) configured with an electrospray 
ionization source (ESI), using nitrogen as nebulizer gas. The acquired data was analyzed with 
Agilent MassHunter qualitative analysis software. Samples were run at four different wavelengths 
(220 nm, 254 nm, 280 nm and 590 nm), in an Eclipse XDB-C18 5 m column, using as solvents: 
Solvent A: H2O:CH3CN:FA (95:5:0.1%); Solvent B: CH3CN:H2O:FA (95:5:0.1%), and the 
following method: Flow rate: 0.5 mL/min., Gradient 10-99% of B in 10min. 
- Calculation of Conversion to Cyclic Peptides and Purity of the Stapling Reactions % of 
conversion to the desired macrocycles was calculated by HPLC. Purities were determined by both 
HPLC and MS (direct injection). 
Quantitative Analysis by HPLC:  
Reaction crudes were injected into the HPLC, after dilution with H2O:CH3CN (same ratio as the 
one used for initial running conditions in the method applied). The threshold of the spectra was set 
to 5%, using as reference the peak with the highest absorbance at 220 nm. Thus, only peaks with 
an absorbance above 5% of the highest peak were taken into account for the calculations, in order 
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to avoid errors resulting from minor peaks due to noise or residual peaks remaining in the column 
from previous injections. 
Conversion was calculated according to the following equation: 
% Conversion = 
𝑨𝑺𝑷
𝑨𝑳𝑷
× 𝟏𝟎𝟎 
where ASP is the area underneath the peak correspondent to the stapled peptide (identified and 
characterized by MS, after analyzing the collected sample correspondent to that retention time), 
and ALP the area underneath the peak correspondent to the linear peptide (identified and 
characterized by MS, after analyzing the collected sample correspondent to that retention time). 
The purity of the cyclic peptide in the reaction crude was calculated according to the following 
equation:  
% Purity = 
𝑨𝑺𝑷
𝑨𝑻𝑷
× 100 
where ATP is the sum of the areas underneath all the peaks above the threshold, excluding the 
injection peaks within first 2 min of the run, and ASP the area underneath the peak correspondent 
to the desired stapled peptide (identified and characterized by MS, as previously indicated).  
All original HPLC chromatograms used for these calculations are showed in this material. 
Quantitative Analysis by Mass Spectrometry:  
Samples were diluted into H2O:ACN (1:1) 1% formic acid. Reaction crudes were directly injected 
into the MS, bypassing the HPLC column, in order to determine accurately the ratio in between 
the components of the mixture. The threshold of the spectra was set to 5%, using as reference the 
peak with the highest intensity. Thus, only peaks with an intensity above 5% of the highest peak 
were considered for the calculations, in order to avoid minor peaks due to noise or residual peaks 
from previous injections.  
Purity was calculated according to the following equation: 
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% Purity = 
𝑰𝑺𝑷
𝑰𝑻𝑷
× 100 
where ITP is the sum of the intensity of all the peaks above the threshold, excluding reference peaks, 
and ISP the sum of the intensity values for all the peaks correspondent to the desired stapled peptide 
(including all the cyclopeptide peaks with different ionization states) 
All original HRMS chromatograms used for these calculations are showed in this material. Spectra 
were zoomed in some cases; irrelevant peak was omitted in any of the zoomed chromatograms.  
All peptides were synthesized manually using polystyrene syringes equipped with a frit and 
following standard Fmoc strategy. Coupling and deprotection steps were carried out as described 
below. Solvents and excess of soluble reagents were removed by vacuum filtration. All the 
peptides were synthesized using Pal (4-Alkoxy-2,6-dimethoxybenzylamine) resin (Bachem D-
2125, 0.5 mmol/g). 
 
- Peptide Elongation 
0.500 g of the resin (PAL resin, BACHEM, f=0.5 mmol/g), were first pre-swelled in DCM (10 
mL, 30 min) and then washed with DMF (5 mL, 3X) and DCM (5 mL, 3X). Next, a coupling 
solution containing the correspondent Fmoc-AA-OH (2.5 eq.), Oxyma (2.5 eq.), PyBop (2.5 eq.) 
and DIEA (5 eq.) in 10 mL DMF was added to the resin. The suspension was carefully transferred 
into a 20-mL microwave vial containing a magnetic stir bar, capped, and reacted under microwave 
irradiation at 85 oC for 7 min. Next, the mixture was transferred back to the solid phase synthesis 
vessel to be subsequently washed with DMF (5 mL, 3X), DCM (5 mL, 3X), EtOH (5 mL 3X) and 
DCM (5 mL 3X).  
The efficiency of the coupling step was assessed by the colorimetric Kaiser test. If a positive Kaiser 
test is obtained, indicative of an incomplete coupling reaction, the resin is treated again with the 
same coupling solution (freshly prepared) and reacted under the conditions described above. After 
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the coupling is complete, the N-terminus of the peptide is Fmoc-deprotected by treating the resin 
with 20 % Piperidine in DMF, 10 min, twice.  Next, the resin is properly washed with DMF (5 mL, 
3X) and DCM (5 mL, 3X), and the efficiency of the deprotection tested by the Kaiser test. This 
iterative process of coupling and deprotection is repeated after the incorporation of each amino 
acid residue, until the full peptide sequence is elongated. Finally, the N-terminus of the peptide is 
acetylated (after Fmoc deprotection, following the same conditions described previously), with a 
solution of acetic anhydride (5 eq.)  and pyridine (5 eq.) under microwave irradiation at 85 oC for 
5 min. For peptides sequences containing serine and/or threonine, these residues were introduced 
as pseudoproline dipeptides containing also the corresponding subsequent amino acid in the target 
peptide sequence. The identity and purity of all the synthesized peptides was assessed by LC/MS 
and HPLC analysis of the solution of a small peptide sample obtained after cleavage, precipitation 
and washed with Et2O.  
 
- 4-methoxytrityl (Mmt) Deprotection and Maleimide test  
Mmt deprotection was carried out with a deprotection solution (15mL per 0.5g of resin, 2% 
TFA, 10% TIS, 88% DCM) at room temperature for 5 min. The resin was then washed with DCM 
(5X) and treated repeatedly with the same solution until its color changed from orange to light 
yellow. Maleimide test was next performed (Scheme S1.4). To this end, a small aliquot of Mmt 
deprotected resin was neutralized with 3mL of 5% DIEA in DMF for 5 min, and washed with 
DMF (2 mL, 3X), DCM (3 mL, 3X) and DMF (3 mL, 2X). The neutralized clean resin was 
subsequently mixed with N-methylmaleimide (5 eq. from a 20 mg/mL DMF stock solution), and 
DIEA (5 eq.) in a 2-mL microwave vial with a stir-bar, and reacted under microwave irradiation 
at 85 oC for 15 min. Next, the suspension was transferred into a SPPS vessel, washed (DMF 2 mL 
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3X, DCM 2 mL 3X) and treated with the proper cleavage cocktail. The resulting peptide is finally 
precipitated/washed with cold diethyl ether and analyzed by LC/MS to quantitate the extent of the 
deprotection step (Scheme S1.4). If the Mmt-deprotection is incomplete, additional deprotection 
rounds are repeated until completion of the reaction. After total Mmt removal is achieved, the resin 
is neutralized with 5% DIEA in DMF for 5 min, washed with DMF (3X) and DCM (3X), and dried 
under vacuum for storage or used directly for the cyclization step. 
 
- Stapling Reaction 
The resin containing the precursor Cys-thiol free linear peptide was transferred into a microwave 
reaction vial containing a stir-bar, to which NaI (17.5 eq for i+4 sequences, 100 eq for i+7 
sequences) and DMF (1mL per 10mg of resin for i+4 sequences, 1 mL per 20 mg of resin for i+7 
sequences) were added subsequently, while keeping the mixture stirring at all times, followed by 
TCEP (0.5 eq for i+4 sequences, 3 eq for i+7 sequences, from a stock solution of 300 mg/mL in 
water). The vial was then capped with a MW vial cap equipped with a rubber septum and the 
resulting suspension bubbled under N2 for 15 min. Next, DIEA (35 eq.) was added (by syringe), 
keeping the stirring under N2 for another 30 min, after which, the dibromoalkyl electrophile was 
injected (3.5 eq for i+4 sequences, 20 eq for i+7 sequences). The suspension is finally reacted 
under microwave irradiation for 2 min at 125oC, transferred into the SPPS reaction vessel and 
washed with water (5 X, soak if necessary to remove residual NaI), DMF (5 X) and DCM (5 X). 
The efficiency of the stapling step was confirmed by cleaving a small aliquot of resin and analyzing 
the precipitated/washed peptide pellet by LC/MS and HPLC.  
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- Final Cleavage  
The peptidyl resin is mixed with the proper TFA cleavage cocktail (TFA/Water/TIS=95/2.5/2.5 
for non-cysteine containing peptides and TFA/Water/TIS/EDT=95/2.5/2.5 for cysteine containing 
sequences). The suspension is then allowed to react on an orbital shaker for 1 h at room temperature 
or under microwave irradiation at 85 oC for 5 min. Next, TFA is evaporated under a stream of 
nitrogen and the peptide precipitated with ice cold Et2O. The resulting pellet is finally washed with 
ice cold Et2O (5X) and isolated by centrifugation. In a typical experiment, 5 mL cleavage cocktail 
were used per each 100 mg of resin, which yielded about 300 mg of crude stapled peptide, and 
overall 75% yield of pure stapled peptide. 
 
- Cleavage Protocol for Sequences Containing S-t-butyl protected cysteine(s) 
StBu deprotection was carried out with a deprotection solution (15mL per 0.5g of resin, 25% 𝛽-
Mercaptoethanol) at room temperature overnight. Maleimide test was next performed to test 
reaction efficiency (Scheme S1.3). To this end, a small aliquot of Mmt deprotected resin was 
neutralized with 3mL of 5% DIEA in DMF for 5 min, and washed with DMF (2 mL, 3X), DCM 
(3 mL, 3X) and DMF (3 mL, 2X). The neutralized clean resin was subsequently mixed with N-
methylmaleimide (5 eq. from a 20 mg/mL DMF stock solution), and DIEA (5 eq.) in a 2-mL 
microwave vial with a stir-bar, and reacted under microwave irradiation at 85 oC for 15 min. Next, 
the suspension was transferred into a SPPS vessel, washed (DMF 2 mL 3X, DCM 2 mL 3X) and 
treated with the proper cleavage cocktail. The resulting peptide is finally precipitated/washed with 
cold diethyl ether and analyzed by LC/MS to quantitate the extent of the deprotection step (Scheme 
S1.3). If the deprotection is incomplete, additional deprotection rounds are repeated until 
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completion of the reaction. After total StBu removal is achieved, the resin washed with DMF (3X) 
and DCM (3X), and dried under vacuum for storage or used directly for the cyclization step. 
 
- Cleavage Protocol for Sequences Containing t-butyl protected cysteine(s) 
The peptide is cleaved, precipitated and properly washed, following the protocol described above 
(Final Cleavage Protocol). The resulting dry pellet, still containing t-butyl protected cysteine(s), is 
then dissolved in a cocktail composed by thiolanisole (4%), EDT (12 %) and TFA (84%) (960 L 
of cocktail per 100mg of peptidyl resin). Next, the mixture is cooled down in an ice bath to 5 oC, 
after which, TFMSA (10% v/v of TFA) is added dropwise (avoiding generation of excessive heat). 
The solution is kept in the ice bath for another 10 min, and then allowed to react at room 
temperature for 1 hour.  Finally, the deprotected peptide is precipitated by adding ice cold Et2O to 
the mixture (5x sample volume). To achieve high precipitation yields, the sample may be left at 
0oC for another 30 min. The crude is isolated by centrifugation and subsequently washed with ice 
cold Et2O (5X). 
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2.9 Appendix: Supplementary Figures 
Figure S 2.1 HPLC analysis of the crude reaction mixtures obtained after cleavage of the stapling 
reactions for the (i, i+4) stapled peptides 2-5, and their correspondent linear precursor 1. 
Experimental conditions used for each HPLC analysis are given in the peptide characterization 
section. 
 
 
Ac-IFEASKKVTCSLSCLISLI-NH2 (1) 
Ac-IFEASKKVT[CSLSC]C3LISLI-NH2 (2) 
Ac-IFEASKKVT[CSLSC]C4LISLI-NH2 (3) 
Ac-IFEASKKVT[CSLSC]C5LISLI-NH2 (4) 
 
Ac-IFEASKKVT[CSLSC]C4eneLISLI-NH2 (5) 
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Figure S 2.2  HRMS analysis of crude reaction mixtures obtained after cleavage of the stapling 
reactions for the (i, i+4) stapled peptides 2-5 and their correspondent linear precursor 1. 
Experimental conditions used for each HRMS analysis are given in the general experimental 
procedure section. Observed 121.05 Da and 922.01 peaks correspond to internal references used 
in the analysis. 
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[M+2H]2
+ 
[M+3H]3
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Figure S2.3 HPLC analysis of the crude reaction mixtures obtained after cleavage of the stapling 
reactions for the (i, i+7) stapled peptides 7-9 and their correspondent linear precursor 6. 
Experimental conditions used for each HPLC analysis are given in the peptide characterization 
section. 
 
 
Ac-IFIASKKVTCSLSNILCIL-NH2 (6) 
 
Ac-IFIASKKVT[CSLSNILC]C7IL-NH2 (7) 
 
Ac-IFIASKKVT[CSLSNILC]C6IL-NH2 (8) 
 
Ac-IFIASKKVT[CSLSNILC]C8IL-NH2 (9) 
 
Linear 
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Figure S 2.4 HRMS analysis of crude reaction mixtures obtained after cleavage of the stapling 
reactions for the (i, i+7) stapled peptides 7-9 and their correspondent linear precursor 6. 
Experimental conditions used for each HRMS analysis are given in the general experimental 
procedure section. Peaks observed at 121.05 Da and 922.01 Da in the HRMS spectra correspond 
to internal references used in the analysis.  
 
 
Ac-IFIASKKVTCSLSNILCIL-NH2 (6) 
[
[M+2H]2+ 
[M+3H]3+ 
[M+2H]2+ 
Ac-IFIASKKVT[CSLSNILC]C7IL-NH2 (7) 
[M+3H]3+ [M+2H]
2+ 
Ac-IFIASKKVT[CSLSNILC]C6IL-NH2 (8) 
 
[M+3H]3+ [M+2H]
2+ 
Ac-IFIASKKVT[CSLSNILC]C8IL-NH2 (9) 
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Figure S 2.5 HPLC analysis of the crude reaction mixtures obtained after cleavage of the stapling 
reactions for the (i, i+4) stapled peptides containing an additional Cys residue 10-12 and their 
correspondent linear precursor S2a. Experimental conditions used for each HPLC analysis are 
given in the peptide characterization section. 
 
 
Ac-QNKCCSRLCKDLL-NH2 (S2a) 
 
Ac-QNKC[CSRLC]C3KDLL-NH2 (10) 
Ac-QNKC[CSRLC]C5KDLL-NH2 (11) 
 
Ac-QNKC[CSRLC]C4KDLL-NH2 (12) 
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Figure S 2.6 HRMS analysis of crude reaction mixtures obtained after cleavage of the stapling 
reactions for the (i, i+4) stapled peptides containing an additional Cys residue 10-12 and their 
correspondent linear precursor S2a. Experimental conditions used for each HRMS analysis are 
given in the general experimental procedure section. Observed 121.05 Da and 922.01 peaks 
correspond to internal references used in the analysis. 
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+ 
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Figure S 2.7 HPLC analysis of the crude reaction mixtures obtained after cleavage of the second 
stapling reaction for the double stapled peptide [2 x (i, i+4)] 14 and its correspondent linear 
precursor 13. Experimental conditions used for each HPLC run are given in the peptide 
characterization section. 
tR
=15.96 min 
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Figure S 2.8 HRMS analysis of crude reaction mixtures obtained after cleavage of the first and 
second stapling reactions for the double stapled [2 x (i, i+4)] 14 and its correspondent linear 
precursor 13. Experimental conditions used for each HRMS analysis are given in the general 
experimental procedure section. Observed 121.05 Da and 922.01 peaks correspond to internal 
references used in the analysis. 
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2.10 Appendix: Peptide’s characterization  
Ac-IFEASKKVTCSLSCLISLI-NH2 (1) 
Isolated from S2, after TFA cleavage, Scheme 1.1 (Main text) 
HRMS (ESI) (m/z): [M] cacld. for C94H162N22O27S2, 2095.1421  
                    [M+2H]2+ found 1048.5774 (monoisotopic peak) 
HPLC: Method 2, tR = 18.74 min. 
 
 
Ac-IFEASKKVT[CSLSC]C3LISLI-NH2 (2) 
 
Synthesis: Using 1,3-dibromopropane as electrophile, Scheme 1.1 (Main text) 
HRMS (ESI) (m/z): [M] cacld. for C97H166N22O27S2, 2135.1734  
            [M+2H]2+ found 1068.5921 (monoisotopic peak) 
HPLC: Method 2, tR = 16.33 min. 
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Ac-IFEASKKVT[CSLSC]C4LISLI-NH2 (3) 
Synthesis: Using 1,4-dibromobutane as electrophile, Scheme 1.1 (Main text) 
HRMS (ESI) (m/z): [M] cacld. for C98H168N22O27S2, 2149.1891 
                  [M+2H]2+ found 1075.6048 (monoisotopic peak) 
HPLC: Method 2, tR = 18.82 min. 
 
 
 
Ac-IFEASKKVT[CSLSC]C5LISLI-NH2 (4) 
 
Synthesis: Using 1,5-dibromopentane as electrophile, Scheme 1.1 (Main text) 
HRMS (ESI) (m/z): [M] cacld. for C99H170N22O27S2, 2163.2047 
                [M+2H]2+ found 1082.6081 (monoisotopic peak) 
HPLC: Method 2, tR = 19.41 min. 
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Ac-IFEASKKVT[CSLSC]C4eneLISLI-NH2 (5) 
 
Synthesis: Using trans-1,4-dibromo-2-butene as electrophile, Scheme 1.1 (Main text) 
HRMS (ESI) (m/z): [M] cacld. for C98H166N22O27S2, 2147.1734 
              [M+2H]2+ found 1074.5926 (monoisotopic peak) 
HPLC: Method 2, tR = 16.21 min. 
 
 
 
Ac-IFIASKKVTCSLSNILCIL-NH2 (6) 
Isolated from S5, after TFA cleavage, Scheme 1.2 (Main text) 
HRMS (ESI) (m/z): [M] cacld. for C96H167N23O25S2, 2122.1530 
               [M+2H]2+ found 1062.0926 (monoisotopic peak) 
HPLC: Method 3, tR = 8.86 min. 
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Ac-IFIASKKVT[CSLSNILC]C7IL-NH2 (7) 
 
 
 
 
 
 
Synthesis: Using 1,7-dibromoheptane as electrophile, Scheme 1.2 (Main text) 
HRMS (ESI) (m/z): [M] cacld. for C103H179N23O25S2, 2218.2469 
         [M+2H]2+ found 1110.1274 (monoisotopic peak) 
HPLC: Method 3, tR = 10.67 min. 
 
Ac-IFIASKKVT[CSLSNILC]C6IL-NH2 (8) 
 
 
 
 
 
 
Synthesis: Using 1,6-dibromohexane as electrophile, Scheme 1.2 (Main text) 
HRMS (ESI) (m/z): [M] cacld. for C102H177N23O25S2, 2204.2313 
         [M+2H]2+ found 1103.1186 (monoisotopic peak) 
HPLC: Method 3, tR = 9.26 min. 
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Ac-IFIASKKVT[CSLSNILC]C8IL-NH2 (9) 
 
 
 
 
 
 
 
Synthesis: Using 1,8-dibromooctane as electrophile, Scheme 1.2 (Main text) 
HRMS (ESI) (m/z): [M] cacld. for C104H181N23O25S2, 2232.2626 
           [M+2H]2+ found 1117.1367 (monoisotopic peak) 
HPLC: Method 3, tR = 10.48 min. 
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Ac-QNKCCSRLCKDLL-NH2 (S4a) 
 
 
Isolated from S7, after subsequent TFA and either S-tBu or t-Bu cleavages, Scheme S1.4 
HRMS (ESI) (m/z): [M] cacld. for C63H113N21O19S3, 1563.7684 
         [M+2H]2+ found 782.8891 (monoisotopic peak) 
HPLC: Method 1, tR = 14.98 min. 
 
 
 
 
 
 
 
 
 
 
 
 
 
HPLC: Crude Reaction Mixture After 
HRMS: Crude Reaction Mixture After 
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Ac-QNKC[CSRLC]C3KDLL-NH2 (S4d) 
 
 
 
 
 
 
Synthesis: Using 1,3-dibromopropane as electrophile, Scheme S1.4 
HRMS (ESI) (m/z): [M] cacld. for C66H117N21O19S3, 1603.7997 
      [M+2H]2+ found 802.9039 (monoisotopic peak) 
HPLC: Method 1, tR = 18.81 min. 
 
 
HPLC: Crude Reaction Mixture After 
HRMS: Crude Reaction Mixture After 
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Ac-QNKC[CSRLC]C4KDLL-NH2 (S4e) 
 
 
 
 
 
 
Synthesis: Using 1,4-dibromobutane as electrophile, Scheme S1.4 
HRMS (ESI) (m/z): [M] cacld. for C67H119N21O19S3, 1617.8153 
         [M+2H]2+ found 809.9116 (monoisotopic peak) 
HPLC: Method 1, tR = 16.89 min 
 
 
 
 
 
 
 
 
 
 
 
 
HPLC: Crude Reaction Mixture After 
HRMS: Crude Reaction Mixture After 
  65 
Ac-QNKC[CSRLC]C5KDLL-NH2 (S4f) 
 
 
 
 
 
 
Synthesis: Using 1,5-dibromopentane as electrophile, Scheme S1.4 
HRMS (ESI) (m/z): [M] cacld. for C68H121N21O19S3, 1631.8310 
         [M+2H]2+ found 816.9188 (monoisotopic peak) 
HPLC: Method 1, tR = 17.36 min. 
 
 
 
 
 
 
 
 
 
 
 
 
HPLC: Crude Reaction Mixture After 
HRMS: Crude Reaction Mixture After 
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Ac-TVDCIASCLSC(StBu)LAEC(StBu)VPQN -NH2 (10) 
 
Isolated from 10, after TFA cleavage, Scheme 1.3 (Main Text) 
HRMS (ESI) (m/z): [M] cacld. for C98H161N23O31S6, 2348.0053 
         [M+2H]2+ found 1175.0092 (monoisotopic peak) 
HPLC: Method 4, tR = 13.67 min. 
 
Ac-TVD[CIASC]C3LS[CLAEC]C3VPQN-NH2 (12) 
 
Synthesis: Using 1,3-dibromopropane as electrophile, Scheme 1.3 (Main Text) 
HRMS (ESI) (m/z): [M] cacld. for C96H153N23O31S4, 2251.9986 
         [M+2H]2+ found 1127.0076 (monoisotopic peak) 
HPLC: Method 4, tR = 15.96 min. 
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Chapter III. Stapled Peptide Inhibitors Polycomb 
Repressive 2 Gene Repression 
3.1 Background 
In eukaryote cells the genetic information is highly compacted inside the nucleus in the form of 
chromatin, which are complexes of DNA and small proteins called histones. The primary function 
of chromatin is not only to make DNA fit into the nucleus but also to dictate how this genetic 
information is used. Thus, chromatin regulates transcription by controlling DNA accessibility to 
the transcriptional cellular machinery. This is achieved through its three-dimensional architecture, 
consisting of two main conformational interphases: a highly condensed and repressive form, 
heterochromatin, in which DNA is tightly wrapped around the core histone proteins and thus 
inaccessible; and a loosely packed permissive state, euchromatin, in which DNA is available for 
transcription. The dynamic interplay between these two structures is mainly controlled by 
epigenetic modifications, including DNA methylation at CpG islands and N-covalent post-
translational chemical modifications on the histone proteins. A balanced pattern of epigenetic 
modifications ensures cell identity and proper function, whereas alterations in the epigenome lead 
to aberrant patterns of gene expression that contribute to the development and progression of 
diseases. 95-96   
 
Cancer is second to cardiac diseases as the most common cause of death in the United 
States and it is expected to become the front-runner by 2030.97 Over the past two decades, 
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reprogramming cancer cells by targeting the cancer epigenome and reorganization of chromatin 
architecture to regulate gene expression has emerged as a promising strategy against this yet 
incurable disease.95 One of the most cancer-relevant epigenetic modifications is the site-specific 
addition of methyl groups into lysine residues on the histone tails. In particular, trimethylation of 
lysine 27 at histone 3 (H3K27me3) has been extensively studied and characterized as a highly 
repressive histone mark, whose dysregulation is strongly linked to a wide array of metastatic 
malignancies. This post-translational modification is installed by the polycomb repressive 
complex 2 (PRC2), a multimeric complex of proteins consisting of four core subunits: EZH2, EED, 
SUZ12 and Rbp46/48. PRC2 transfers one to three methyl groups from S-adenosyl-L-methionine 
(SAM) onto the amino group of H3K27, generating H3K27me3, thus subsequently silencing 
downstream genes through chromatin compaction. The enzymatic activity of PRC2 is conferred 
by the catalytic SET domain of EZH2, but also to the other core components of the complex, since 
EZH2 does not show methyltransferase activity on its own, neither is structurally stable. Hence, a 
catalytically active PRC2 complex must contain EZH2 and at least EED and SUZ12, which 
highlights the role of the latter proteins as scaffolds for the proper assembly of PRC2 into its 
bioactive conformation. 98-100 
The physiological relevance of the PRC2 is highlighted by the early embryonic lethality 
observed in mice after genetic ablation of genes encoding for PRC2-proteins. Moreover, extensive 
evidences show that PRC2 is dysregulated in multiple human cancers101-103.For example, gain of 
function mutations of EZH2 at residues within the SET domain (A677 and Y641), with higher 
catalytic power yielding to increased H3K27me3 levels, have been found in melanoma and B-cell 
lymphoma. PRC2 proteins, and in particular EZH2, have also been found overexpressed in solid 
cancers including colorectal, breast, ovarian, kidney, lung, bladder, prostate, pancreatic and 
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sarcomas, and their upregulation correlates with advance stages of the disease and poor prognosis 
104-106. Furthermore, EZH2 methylates several cytosolic non-histone proteins in a PRC2-dependent 
manner such as STAT3 in glioblastoma promoting tumorigenesis.104 
The pivotal role of PRC2 in multiple oncogenic processes has made PRC2 proteins highly 
attractive molecular targets for developing promising anticancer agents. Hence, the discovery of 
such compounds is an area of active research for both the pharmaceutical industry and academic 
laboratories. Several potent PRC2 inhibitors have been discovered in the last few years. Some of 
them are already undergoing clinical investigation with promising results. All these first-
generation compounds are competitors of the methyl donating cofactor SAM and target the 
catalytic SET domain of EZH2. They are also structurally related since most share as central 
feature a pyridine scaffold that serve as key pharmacophore to recognize the SET-domain binding 
pocket. These small molecules have proven to be highly effective at reducing H3K27me3 levels 
in vitro and in vivo, and potent inhibitors of cancer cell proliferation and tumor growth. Indeed, 
Tazemotstat (Epizyme), GSK126 (GlaxoSmithKline), and CPIC-1205 (Constellation 
Pharmaceuticals) are some examples of EZH2 inhibitors under evaluation in phase 1/2 clinical 
trials for a variety of cancers, including advanced solid tumors107. However, recent reports indicate 
that extended dosing with these drugs leads to secondary EZH2 mutants resistant to treatment108-
111. Such resistance profiles raise concerns about the potential of these compounds, especially since 
they share the same mechanism of action.107 Hence, novel PRC2 inhibitors targeting the PRC2 
complex at other crucial protein-protein interphases are of great interest, since they constitute a 
potential solution to address this problem. Indeed, this alternative strategy has been recently 
validated by the discovery of a second generation of PRC2 modulators, designed to block the 
H3K27me3 binding pocket in EED112. Notably, these compounds efficiently block H3K27me3 
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levels in both cell lines sensitive and resistant to EZH2-SET domain inhibitors, and result in strong 
efficacy against mice and human tumor xenograft models. In this chapter, we describe the design, 
synthesis and biological evaluation of three different families of cyclopeptide inhibitors of PRC2 
catalytic function, targeting for the first time three protein interfaces in PRC2 that are crucial for 
its proper assembly and function: the intramolecular SANT1L/SBD interaction of EZH2, the 
SUZ12-VEFS/EZH2-SANT2 binary complex and the interaction between SUZ12-NBE domains. 
All the compounds described herein have been generated using the solid phase synthetic approach 
described in Chapter 1. Our inhibitors have demonstrated cell permeability, potent activity in vitro 
and in physiological conditions, as well as strong antiproliferative effects on Caki-1 renal cancer 
cells. 
3.2 Bisthioether Stapled Peptides as Allosteric Inhibitors of PRC2 Targeting the SANT1L-
SBD Interaction in EZH2. 
A recently published crystal structure of an active PRC2 ortholog from yeast revealed 
several interactions among its core components thought to be crucial for both proper PRC2 
assembly and function (PDB ID 5KJH)99. Based on this structure, we designed a series of stapled 
peptides inhibitors of PRC2 methyltransferase activity, targeting a key intramolecular interaction 
in EZH2 formed by its SANT1L-like domain (Figure 3.2.1a, left, orange alpha-helix) and its 
SANT1L-binding domain (SBD, Figure 3.2.1a, left, grey alpha-helix). This binary alpha-helical 
complex surrounds EED, another core PRC2 protein, forming a belt-like structure around it, and 
thus plays a crucial role in stabilizing the bioactive catalytic conformation of PRC2. Our design 
focused on mimicking an alpha helix formed by the SBD domain in EZH2 in order to generate 
macrocycles that could potentially bind to SANT1L, and thus disrupt the key SBD-SANT1L 
intramolecular interaction in PRC2 (Figure 3.2.1a, right).  
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Figure 3.2.1 Bis-thioether Stapled Peptide Design Left: The crystal structure of an active Ezh2-
Eed-Suz12(VEFS) PRC2 complex ortholog from yeast (PDB ID 5KJH)99 revealed key interactions 
for PRC2 catalytic structure and function. Top Right: Zoomed alpha-helical intramolecular 
interaction in between the SBD (colored gray) and SANT1L (colored orange) EZH2 domains. 
Bottom Right: Structure of the designed stapled peptide inhibitors targeting the SBD-SANT1L 
interaction in EZH2, using the same color coding. All cyclopeptides are derived from the SBD 
wild type sequence 1, residues 198-216 in EZH2. Solvent-exposed amino acids were mutated to 
Cys for peptide stapling (colored pink for single- and yellow for double-turn stapling).  
 
Based on these structural considerations we successfully prepared five macrocycles, in 
which solvent-exposed residues were replaced by cysteines for the planned stapling reaction. The 
synthesis was accomplished successfully, following the synthetic methodology previously 
described in Chapter 1 (Schemes 3.2.1 and 3.2.2). The crude of the corresponding cyclopeptides 
were purified by HPLC, affording the final products with purities >95%.  
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Scheme 3.2.1 Synthetic scheme for the chemoselective preparation of single turn stapled peptides 
(i, i+4) inhibitors of the intramolecular SANT1L-SBD interaction in EZH2. 
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Scheme 3.2.2 Synthetic scheme for the chemoselective preparation of double turn stapled peptides 
(i, i+7) inhibitors of the intramolecular SANT1L-SBD interaction in EZH2. 
 
 
We first investigated the impact of the staple on the secondary structure of our synthesized 
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macrocycles by circular dichroism (CD). The analysis of the linear wild type peptide revealed that 
it was only 4.8% helical in solution, indicating that this sequence is almost disordered when it is 
removed from the full protein structure. Interestingly, incorporation of the hydrocarbon brace 
resulted in enhanced helical character for both single- and double-turn stapled peptides. 
Remarkably, compound 2 showed the best result, with an overall improvement of 18% in helicity 
(Figure 3.2.2 a,b). Next, we tested our cyclopeptides for their ability to inhibit H3K27 
trimethylation in vitro. To this end, we optimized a histone methyltransferase colorimetric assay 
using as catalytic complex endogenous PRC2 extracted from a human clear cell renal carcinoma 
cell line (Caki-1). A well-characterized EZH2-SET domain inhibitor (GSK126) was used as a 
positive control for determining optimal assay conditions113. Both single- and double-turn stapled 
peptides showed concentration dependent inhibition of PRC2 catalytic function. In line with the 
CD data, the best inhibitor was compound 2 with an IC50 value of 0.17  0.02 M. This staple 
peptide was virtually as potent as GSK126 in the same assay conditions and over 500 times better 
than its linear wild type counterpart 1 (Figure 3.2.2a).  Aiming at gaining insights about the 
mechanism of action of cyclopeptide 2 for PRC2 inhibition, we decided to also explore its potential 
synergy with the EZH2-SET domain inhibitor GSK126. Hence, we performed the previously 
optimized enzymatic in vitro assay, using an equimolar combination of both compounds. To 
quantitatively assess synergy, we used the combination index (CI) equation of Chou et al., for 
which a value of CI<1 is indicative of a more than additive outcome.114 Notably, the equimolar 
mixture of 2 and GSK126 yielded an IC50 value of 0.031  0.001M, which corresponded to a CI 
of 0.53. This data suggest that our compound may works synergistically when applied in 
combination with an inhibitor of the catalytic SET domain of EZH2, and therefore, that it may 
likely function by blocking a different PRC2 domain, key for its function, i.e, in an allosteric 
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fashion (Figure 3.2.2c).  
Figure 3.2.2 Biochemical Assays (a) Structure of the synthesized stapled peptides, and their 
correspondent helicity and IC50 values for inhibition of H3K27 trimethylation in vitro, as 
determined by a histone methyltransferase colorimetric assay optimized using endogenous PRC2 
extracted from a human clear cell renal carcinoma cell line (Caki-1). (b) CD spectra of stapled 
peptides and their linear counterparts measured in water at 20oC. (c) Plot of H3K27 trimethylation 
inhibition using the enzymatic in vitro assay described in a, with varying concentrations of 2, 
positive control GSK126, and using an equimolar combination of both compounds to test their 
synergistic effects. The IC50 values obtained when using recombinant PRC2 and when using a high 
concentration of SAM (110 X) are also shown. A summary of the IC50 values for inhibition of 
H3K27me3 determined from the experiments shown in plot c. is also presented. Calculation of the 
combination index using the equation described by Chou et al. (CI= 0.53) indicated a marked 
synergistic effect between 2 and GSK126. 
 
In order to get more insights into the potential allosteric nature of inhibitor 2, we performed 
the same H3K27me3 inhibition assay but using instead a larger concentration of SAM (100 folds, 
Figure 3.2.2c). Since the methyl-donor cofactor has been proven to bind directly to the EZH2-SET 
domain, using a larger concentration of it would directly impact the potency of any other molecule 
targeting the same binding site, as it has been shown previously with other well characterized 
orthosteric PRC2 inhibitors112, 115. As expected, in our case, the IC50 obtained in such experimental 
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conditions was similar to the original value, which demonstrates that our cyclopeptide is not a 
SAM-competitor inhibitor, thus reinforcing the previous data that suggested the allosteric nature 
of peptide 2. 
Aiming at obtaining more evidences toward the specific target site of 2 within the PRC2 
complex, we performed a pull-down assay over nuclear extracts isolated from caki-1 cells and 
using a biontinylated derivative of it (Figure 3.2.3). The assay was performed according to the 
manufacture’s protocol. Briefly, the biotinylated peptide 2 was incubated with streptavidin coated 
beads in a fritted syringe overnight. Next, after thoroughly washing of the beads, nuclear extract 
was applied to the syringe and incubated with the beads for 1 hour.  The beads were then washed 
thoroughly in order to remove the non-binding proteins, followed by isolation of the prey-proteins 
by carrying out washes with the elution buffer. As shown in Figure 3.2.3, western blot analysis of 
the prey-protein solutions indicated the presence of EZH2 in the mixture previously treated with 
biotinylated 2, whereas no EED or SUZ12 were detected in this sample.  Neither of these proteins 
were found in the solution derived from the vehicle treatment (control). Thus, this data suggests 
that our cyclopeptide 2 does bind to EZH2 selectively. 
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Figure 3.2.3  (a) Structure of the biotinylated derivative of cyclopeptide 2, synthesized on solid 
phase (b,c) In vitro pull down assay using biotinylated cyclopeptide 2, visualized by SDS-PAGE 
and followed by western blot analysis using antibodies against human EZH2 (b) and human EED 
and SUZ12 (c). 
 
Altogether, the results from these biochemical assays show, first, that cyclopeptide 2 is a 
potent inhibitor of PRC2 catalytic function, and more importantly that it may function 
allosterically. Further evidences indicate that this compound targets EZH2, not as a SAM-
competitor inhibitor, and thus it may likely mimic the EZH2-SBD domain and therefore act by 
disrupting the crucial SBD-SANT1L intramolecular interaction. 
 
Next, we tested the proteolytic stability of these compounds by subjecting two 
representative examples to a chymotrypsin-based assay previously validated to evaluate the 
stability of stapled peptides.116 For comparison, we also studied their linear counterparts. HPLC 
and LC/MS analysis of the enzymatic reactions showed complete protection of both i+4 and i+7 
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cyclopeptides against enzymatic degradation after 24h, whereas its linear analogue underwent full 
hydrolytic cleavage one hour after the reaction started (Figure 3.2.4). In addition, we tested the 
stability of cyclopeptide 2 and its parent linear sequence 1 in plasma.69 In line with the in vitro 
assay results, our macrocycle showed high resistance to proteolysis in these conditions, resulting 
also markedly superior to peptide 1, which was fully degraded after 5 minutes.  Overall, we 
conclude that our stapling reaction leads to significant protection against enzymatic degradation, 
thus making this family of constrained peptides suitable for cellular and biological assays. 
Figure 3.2.4 The Chymotrypsin-based proteolytic degradation assays as well as the plasma 
stability assay show remarkable stability of our i, i+4 and i, i+7 bisthioether stapled peptides. The 
rate of peptide proteolysis was monitored by HPLC and HPLC-MS analysis.  
 
Given the encouraging in vitro H3K27me3 inhibition data and the proteolytic stability 
shown by our stapled peptides, we decided to explore the cellular uptake of compound 2 by 
confocal microscopy, using an FITC-labeled derivative of it. Confocal imaging after incubation of 
caki-1 cells with fluorescently-tagged 2 showed significant membrane translocation of the stapled 
peptide. More importantly, these experiments also confirmed that this compound is able to reach 
the nuclei, where the targeted PRC2 complex is localized (Figure 3.2.5). 
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Figure 3.2.5 Confocal microscopy images of Caki-1 cells, scale bar 10 m (a) Cells were treated 
with 5M of FITC-labeled 13 at 37oC for 5h. 60X magnification (b) Vehicle, cells were treated 
with 1% dmso in PBS at 37oC for 5h. 60X magnification. 
 
To further explore the ability of cyclopeptide 2 to target and functionally block PRC2-
mediated H3K27 methylation, we treated Caki-1 cells for 72h with varying concentrations of 2 
and analyzed all degrees of methylation on K27 by western blot. We used GSK126 (1 M) and 
the linear wild type peptide sequence 1 (25 M, 100 M) as positive and negative control, 
respectively (Figure 3.2.6).   
Caki-1 Cells Treated with 2-FITC Caki-1 Cells Treated with 1% a b 
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Figure 3.2.6 Cellular Assays with lead bisthioether stapled peptide 2 (a) Western blot analysis 
shows dose-dependent response of H3K27me3, H3K27me2 and H3K27me1 within caki-1 cells, 
after treatment with stapled peptide 2 once daily for 72h. Single concentration treatment with 
GSK126 (positive control) and linear wild type sequence (1, negative control) in the same 
experimental conditions are also shown. Quantitation of H3K27me3 using and absorbance-based 
colorimetric assay yielded an IC50 value of 0.4  0.2 M. Protein loading was accurately corrected 
by measuring total H3 using an absorbance-based colorimetric assay. (b) Selectivity of H3K27 
trimethylation inhibition over a broad panel of histone post-translational modifications. Cells were 
treated with stapled peptide 2 (5 M) or vehicle, once daily for 72h. (c) Treatment of Caki-1 cells 
with cyclopeptide 2, control compound GSK126, and an equimolar combination of both molecules 
significantly inhibits cell proliferation. Proliferation was measured after 72h of daily treatment 
with the correspondent compound. The data is presented as a mean of two independent 
experiments each with triplicate measurements. (d) Plot of IC50 values obtained when testing our 
lead compound 2, GSK126 and a combination of both in: (d.1) an enzymatic in vitro assay 
monitoring H3K27me3 inhibition, using endogenous PRC2 extracted from a human clear cell renal 
carcinoma cell line (Caki-1), (d.2) a proliferation colorimetric assay with Caki-1 cells, (d.3) in 
non-cancerous human fibroblast IMR90 cells. Calculation of the combination index using the 
equation described by Chou et al. indicated a marked synergistic antiproliferative effect (CI= 0.61) 
when both compounds are used together. 
The results showed a clear concentration-dependent inhibition of 2, most pronounced for 
trimethylation but also significant for H3K27me2 and H3K27 monomethylation (Figure 3.2.6a). 
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Further quantitation of H3K27me3 by an absorbance-based colorimetric assay yielded an IC50 of 
0.4  0.2 M, similar to that obtained in our in vitro enzymatic functional assay (Figure 3.2.6a). 
We conclude that our stapled peptide is cell permeable and a potent inhibitor of relevant 
physiological methylation of the PRC2 substrate. Remarkably, compound 2 also shows 
exceptional selectivity for H3K27 trimethylation inhibition. Thus, western blot analysis of histones 
isolated from cells treated with either high concentration of our cyclopeptide 2 (5 M) or vehicle 
control showed no effect on H3K4me3, H3K9me3, H3K36me2, H3K79me2 and H3K27Ac, 
whereas total inhibition of H3K27me3 was observed in the same experimental conditions (Figure 
3.2.6b). 
Finally, we investigated the impact of H3K27m3 inhibition on cell growth and proliferation 
of Caki-1 cells, using healthy lung fibroblast cells IMR90 as a control. Cells were treated with 
compound 2, GSK126 as a positive control, and an equimolar combination of both compounds for 
72h. Proliferation assays indicated that both cyclopeptide 2 and GSK126 are capable of 
significantly arresting cell growth, with IC50 values of 0.25  0.03 M and 0.15  0.06 M, 
respectively, as quantified by a colorimetric method (Figure 3.2.6c). More notably, a combination 
of both compounds yielded an IC50 value of 0.06  0.01M with a combination index of 0.61, 
indicative of a marked synergistic antiproliferative effect. Similar results were obtained in the 
correspondent viability assays. The compounds displayed no cytotoxicity below 15M in non-
cancerous human fibroblast IMR90 cells (Figure 3.6d).  
In summary, we have applied our previously developed synthetic approach to generate 
macrocycles that effectively disrupt a biologically relevant intracellular protein-protein interaction 
in the PRC2 complex. In particular, we describe a series of cyclopeptide inhibitors of PRC2 
methyltransferase activity, designed to target the intramolecular SANT1L-SBD interaction in 
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EZH2. Compared to their linear counterparts, these compounds showed enhanced -helical 
structure and inhibition of target function. Our lead cyclopeptide 2 showed potent inhibition of 
H3K27 trimethylation in both in vitro and cellular assays, demonstrating that it is cell permeable 
and active in physiological conditions. Inhibition of PRC2 catalytic activity by 2 produced a 
marked dose-dependent antiproliferative effect in metastatic Cakis-1 cells. Notably, in these 
experiments our compound was almost as effective as GSK126, an EZH2 inhibitor currently in 
clinical development.113  
 
3.3 Bisthioether Stapled Peptides as Allosteric Inhibitors of the SUZ12-VEFS/EZH2-
SANT2 Interaction   
The rational design of this family of stapled peptides focused on an interaction between the 
VEFS domain of SUZ12 (SUZ12-VEFS) and the catalytic subunit EZH2. In particular, we aimed 
at mimicking two different -helical bundles of SUZ12-VEFS, which had been documented to 
play a critical role in PRC2 proper assembling and function, through their interaction with EZH2 
(Figure 3.3.1).98, 117-118  These evidences have also been confirmed by the resolution of a crystal 
structure of an active PRC2 ortholog from yeast5, and more recently, of the cryo-electron 
microscopy structures of a complete human PRC2 complex (PDB ID 6C23)98. Based on these 
structural considerations, we designed a series of stapled peptides derived from the human 
sequence of the SUZ12-VEFS domain, residues 590-603 and 652-669, respectively. 
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Figure 3.3.1 Left: The cryo-electron microscopy structure of a complete human PRC2 complex 
(PDB ID 6C23)98. Top Right: Zoomed -helical intramolecular interaction between the targeted 
VEFS-SUZ12 (colored purple, yellow and gray) and EZH2 domains (colored Cyan). Bottom Right: 
Structure of the designed stapled peptide inhibitors, with the Cys residues incorporated for stapling 
labelled in green. 
 
A total of four macrocycles, in which solvent-exposed residues were replaced by cysteines 
for the planned stapling reaction, were successfully prepared following a synthetic methodology 
previously presented in chapter 1 (Schemes 3.3.1 and 3.3.2). 
 
VEFS
7 10 11,128,9
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Scheme 3.3.1 Synthetic scheme for the preparation of single turn stapled peptides (i, i+4) mimetics 
of the SUZ12-VEFS domain, residues 590-603, as inhibitors of PRC2 methyltransferase activity. 
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The synthesis of all the compounds was accomplished successfully as planned. The crude 
of the corresponding cyclopeptides were purified by HPLC, affording the final products with 
purities >95%.  
Scheme 3.3.2 Synthetic scheme for the preparation of single turn stapled peptides (i, i+4) mimetics 
of the SUZ12-VEFS domain, residues 652-669, as inhibitors of PRC2 methyltransferase activity. 
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Figure 3.3.2 (a) Structure of the designed stapled peptides and summary of results obtained in the 
biochemical assays (b) Both Chymotrypsin-based proteolytic degradation and the plasma assay 
show enhanced stability of i, i+4 bisthioether stapled peptides. (c) CD spectra of stapled peptides 
and their linear counterparts measured in water at 20oC. (d) Inhibition of PRC2 catalytic function 
(H3K27Me3) as determined in an enzymatic assay using endogenous PRC2 extracted from a 
human clear cell renal carcinoma cell line (Caki-1), at peptide concentration of 10 M (e) Plot of 
H3K27me3 inhibition obtained in an enzymatic assay using endogenous PRC2 extracted from 
Caki-1 cells and recombinant PRC2 complex, 100SAM, and equimolar combination with 
GSK126 (for compound 11).  
 
We first investigated the proteolytic stability of these compounds by subjecting them to 
both a chymotrypsin and a plasma stability assay69, 116.  For comparison, we also studied their linear 
counterparts. HPLC and LC/MS analysis showed in both assays marked protection of our i, i+4 
cyclopeptides to proteolysis, in contrast to their respective linear analogues, which were fully 
degraded after a few minutes in both conditions (Figure 3.3.2a, b). Next, we measured the impact 
of the staple on the secondary structure of our synthesized macrocycles by circular dichroism (CD). 
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This analysis indicated that stapling through a three-methylene hydrocarbon brace resulted in 
remarkable enhancement of the helical character for both series, more pronounced for compound 
11, which showed an overall helicity of 95% (Figure 3.6a, c). 
To test if the observed induction of helical conformation correlated with biological activity, 
we investigated our cyclopeptide’s ability to inhibit H3K27me3 in an enzymatic assay, using as 
catalytic complex endogenous PRC2 extracted from a human clear cell renal carcinoma cell line 
(Caki-1). A well-characterized EZH2-SET domain inhibitor (GSK126) was used as a positive 
control for determining optimal assay conditions. A first screening at 10 M peptide concentration 
showed that all compounds were capable of inhibiting H3K27me3. In line with the CD results, 
cyclopeptide 11 resulted the more potent of both series (Figure 3.3.2a, d). Further testing of this 
compound showed concentration dependent inhibition of PRC2 catalytic function with an IC50 
value of 0.32  0.10 M, resulting virtually as potent as GSK126 in the same assay conditions. 
The specificity of 11 (GN-ZW11) for targeting PRC2 complex assembly and function was then 
confirmed by performing the same enzymatic assay with pure recombinant PRC2 complex, which 
yielded almost the same result (Figure 3.3.2e). We further confirmed the allosteric nature of this 
inhibitor by performing the same inhibition assay using a much higher SAM concentration (100 
folds) than the in original conditions, which led to similar IC50 value of 0.28  0.10 M (Figure 
3.3.2e). In line with this result, we also observed strong synergy between compound 11 and 
GSK126, a SAM-competitor inhibitor, when carrying out the same H3K27me3 inhibition assay 
using equimolar amount of both molecules. Thus, the combination index calculated as described 
before resulted in a value of 0.28, well below the limit set for a synergistic and not additive effect 
(CI < 1). 
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We next explored the cellular uptake of 11 by confocal microscopy, using an FITC-labeled 
derivative of it. Confocal imaging after incubation of caki-1 cells with fluorescently-tagged 11 
showed that it penetrates the cell membrane, and more importantly that it reaches the nuclei, where 
the targeted PRC2 complex is localized (Figure 3.3.3a). Next, encouraged by these results, we 
studied the ability of 11 to target and functionally block PRC2-mediated H3K27me3 in Caki-1 
cells. We also evaluated, as controls, the cyclopeptides of both series 7-9, 10 and 12. In line with 
the results previously obtained in the enzymatic assay, western blot analysis after cell treatment 
for 72h at 10 M peptide concentration indicated that only 11 was able to efficiently block 
H3K27me3 (Figure 3.3.3b). Further testing with varying concentration of this compound showed 
a clear dose-response inhibition of PRC2 catalytic function with an IC50 of 1.04  1.34 M, which 
is also similar to that obtained in our enzymatic assay (Figure 3.3.3c). To assess the selectivity of 
our compound for targeting the PRC2 complex, we investigated its effect on different post-
translational modifications. Remarkably, cyclopeptide 11 showed exceptional selectivity for 
H3K27Me3 inhibition. Thus, western blot analysis of histones isolated from cells treated with 
either high concentration of 11 (5 M) or vehicle control showed no effect on H3K4me3, 
H3K9me3, H3K36me2, H3K79me2 and H3K27Ac, whereas total inhibition of H3K27me3 was 
observed in the same experimental conditions (Figure 3.3.3d). Altogether, this data confirmed that 
our stapled peptide is cell permeable and a potent selective inhibitor of the relevant physiological 
methylation of the PRC2 substrate. 
  89 
Figure 3.3.3 (a) Confocal microscopy images of Caki-1 cells, scale bar 10 m. Cells were treated 
with FITC-labeled 11 (5 M) and control peptide (-Ala--Ala-FITC, 5 M) at 37oC for 5h. (b) 
Western blotting after treating caki-1 cells with both series of peptides at 10 M shows marked 
inhibition of H3K27me3 by compound 11, in contrast to the control peptides (c) Western blot 
analysis after treatment of caki-1 cells with varying concentration of stapled peptide 11, once daily 
for 72h, indicates a clear dose-dependent response of H3K27me3. Single concentration treatment 
with GSK126 (positive control) and linear wild type sequence 16 (negative control) are also shown. 
(d) Selectivity of H3K27 trimethylation inhibition over a broad panel of histone post-translational 
modifications. Cells were treated with stapled peptide 11 (5 M) or vehicle, once daily for 72h. 
 
In summary, our structure-based approach has allowed the identification of a series of 
cyclopeptide inhibitors of PRC2 methyltransferase activity, designed to target the interaction 
between the VEFS domain of SUZ12 and the SANT2 domain of EZH2, the catalytic subunit of 
PRC2. In particular, one of our stapled peptides (11) showed potent inhibition of H3K27 
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trimethylation in both in vitro and cellular assays, which demonstrate that it is cell permeable and 
active in physiological conditions. 
 
3.4 Bisthioether Stapled Peptides as Allosteric Inhibitors of the SUZ12-NBE/Nurf55 
Domain Interaction   
The rational design of this family of stapled peptides focused on targeting an -helical 
interaction between Nurff55 and the Nurf55 binding epitope (NBE) domain of SUZ12 (SUZ12-
NBE), which have been shown to play a key role in the PRC2 recruitment onto nucleosomes and 
thus in its methyltransferase activity. More specifically, these compounds are mimetics of the helix 
α1 of Nurf55, residues 20-35, which interacts with the SUZ12-NBE domain, and therefore 
constitute a new family of peptidomimetic modulators of SUZ12-NBE function.119 
We designed a total of 21 macrocycles, aiming at testing four different families of stapled 
peptides cross-linked at four different positions in the native linear peptide sequence (Figure 3.4.1).   
The synthesis was accomplished successfully, following the solid phase protocol described in 
Chapter 1 via orthogonal Fmoc strategy. The all-hydrocarbon staples were installed 
chemoselectively by forming a bisthio-ether linkage, after selectively deprotecting the Mmt (4-
methoxyltrityl) protecting groups from the corresponding cysteines residues.  A representative 
example of the synthesis of the compounds of this series is given in Scheme 3.4.1 
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Figure 3.4.1 Top: Crystal structure of Nurf55 in complex with SUZ12-NBE (PDB 2YB8)119. 
Center: Zoomed -helical intramolecular interaction between Nurff55 and the Nurf55 binding 
epitope (NBE) domain of SUZ12 (SUZ12-NBE). Bottom: Structure of the designed stapled 
peptide inhibitors, mimetics of the helix α1 of Nurf55, residues 20-35, with the Cys residues 
incorporated for stapling labelled in purple. 
 
1,2 5,6 7,8
Wild Type Peptide
3,4
Stapled Peptides i+4
1 1 2 2
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Scheme 3.4.1 Synthetic scheme for the preparation of single turn stapled peptides 24-28 (i, i+4), 
as mimetics of the helix α1 of Nurf55, residues 20-35, targeting the SUZ12-NBE domain.  
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Following cyclization, the resulting macrocycles were cleaved off the resin with a 
trifluoroacetic acid (TFA) cocktail (TFA/EDT/Water/TIS=94/2.5/2.5/1) and precipitated from 
diethtyl ether. Finally, the cyclopeptide crudes were purified by semipreparative HPLC, yielding 
the desired products in good overall yields and with purities >95%. Characterization was 
performed by analytical HPLC and LC/MS.  
We first measured the effect of incorporating different bis-thioether staples at different 
positions in the sequence, on the helicity of the resulting macrocycles by circular dichroism (CD). 
As expected, both the position and the length of the linker resulted key factors on stabilizing the 
bioactive alpha-helical conformation.  Each family of stapled peptides showed several candidates 
with improved -helicity, compared with linear parent sequence 13 (Figure 3.4.2). Compound 24 
showed the highest helical character of the whole series, with an improvement of 20% over 13 
(Figure 3.4.2a, b).  
To determine if the conformational effects induced by the incorporation of the staples 
would translate into a potent inhibition of PRC2 methyltransferase activity, we next subjected all 
the synthesized macrocycles to an enzymatic assay specific for H3K27Me3, using as catalytic 
complex endogenous PRC2 extracted from a human clear cell renal carcinoma cell line (Caki-1). 
A well-characterized EZH2-SET domain inhibitor (GSK126) was used as a positive control for 
determining optimal assay conditions. An initial screening of all the compounds at a concentration 
of 10 M showed a high correlation between helical character and inhibitory activity (Figure 3.4.2). 
Interestingly, the best inhibitor of each series was the cyclopeptide resulting from stapling through 
a three-methylene hydrocarbon linker.  
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Figure 3.4.2 (a) Structure, helicity and % of inhibition of H3K27me3 at 10 M for all the 
synthesized stapled peptides (b) Bar graph showing the helicities and percentages of H3K27me3 
inhibition at 10 M peptide concentration, for all the synthesized stapled peptides and the linear 
analogue 13 (c) CD spectra of each of the peptides that showed the higher helical character from 
each family, measured in water at 20oC. 
 
Further analysis of these compounds under the same enzymatic assay confirmed that they 
were able to efficiently block PRC2 catalytic activity, with IC50 values in the low micromolar 
range (Figure 3.4.3a,b). In particular, stapled peptide 24 was the most potent compound with an 
IC50 of 1.33  1.36 M, markedly superior to that of its linear parent peptide 13. To unequivocally 
demonstrate that the inhibition of H3K27me3 shown by compound 24 is specifically due to 
inactivation of PRC2 methyltransferase activity, we carried out the same enzymatic assay using 
instead pure recombinant PRC2. The IC50 obtained in such conditions (1.78  0.32 M) was almost 
identical to that previously determined when using the caki-1 cell’s nuclear extract as complex 
source, which confirmed the molecular target of our stapled peptide (Figure 3.4.3c).  
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14 Ac-VI[CEEYC]C3IWKKNTPFL 98.7 12.67 83.84 25 Ac-V[CNEEC]C4KIWKKNTPFL 97.8 13.1 67.49
15 Ac-VI[CEEYC]C4IWKKNTPFL 99.3 11.49 48.13 26 Ac-V[CNEEC]C4eneKIWKKNTPFL 96.8 17.06 68.58
16 Ac-VI[CEEYC]C4eneIWKKNTPFL 99.5 18.97 78.08 27 Ac-V[CNEEC]C5KIWKKNTPFL 97.8 13.64 74.06
17 Ac-VI[CEEYC]C5IWKKNTPFL 96.7 10.98 48.49 28 Ac-V[CNEEC]C6KIWKKNTPFL 97.8 16.34 39.73
18 Ac-VI[CEEYC]C6IWKKNTPFL 97.7 19.41 50.87 29 VINEEYKIWKKN[CPFLC]C3 96.8 20.73 90.96
19 Ac-VINEEY[CIWKC]C3NTPFL 98.6 18.36 85.75 30 VINEEYKIWKKN[CPFLC]C4 97.6 15.64 42.30
20 Ac-VINEEY[CIWKC]C4NTPFL 97.3 16.49 68.58 31 VINEEYKIWKKN[CPFLC]C4ene 99.1 22.25 45.39
21 Ac-VINEEY[CIWKC]C4eneNTPFL 98.1 24.2 70.41 32 VINEEYKIWKKN[CPFLC]C5 98.9 22.69 43.38
22 Ac-VINEEY[CIWKC]C5NTPFL 97.1 5.68 48.49 33 VINEEYKIWKKN[CPFLC]C6 97.1 22.45 44.84
23 Ac-VINEEY[CIWKC]C6NTPFL 96.9 19.41 50.32
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Figure 3.4.3  (a) Inhibition of PRC2 catalytic function (H3K27Me3) by the most potent stapled 
peptides of each series, as determined in an enzymatic assay using endogenous PRC2 extracted 
from a human clear cell renal carcinoma cell line (Caki-1) (b) Plot of H3K27 trimethylation 
inhibition using the enzymatic in vitro assay described in a (c) Plot of H3K27 trimethylation 
inhibition using the enzymatic in vitro assay described in a, with varying concentrations of 24 
(using both endogenous PRC2 extracted from a human clear cell renal carcinoma cell line and 
recombinant PRC2), positive control GSK126, and using an equimolar combination of both 
compounds to test their synergistic effects. (d) Plot of H3K27 trimethylation inhibition using the 
enzymatic in vitro assay described in a, with varying concentrations of SAM. (e) A summary of 
the IC50 values for inhibition of H3K27me3 determined from these experiments is shown in plot 
b,c and d.  
 
We further examined the potential synergy of 24 with GSK126, a well-characterized 
EZH2-SET domain inhibitor currently in clinical development. To this end, we performed the 
previously described inhibition assay, using an equimolar combination of both 24 and GSK126, 
which yielded an IC50 value of 0.08  0.09 M. This value corresponds to a combination index 
(CI) of 0.55, indicative of a marked synergistic effect between the two compounds (Figure 3.4.3c). 
The synergy observed strongly suggests that our stapled peptide targets PRC2 allosterically. To 
finally confirm this hypothesis, we carried out our H3K27me3 inhibition assay at different 
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concentrations of S-adenosyl-L-methionine (SAM). These experiments showed that the binding 
of 24 is independent of SAM concentration, and thus that our cyclopeptide does not compete with 
it for the binding to the SET domain of EZH2, and therefore targets PRC2 allosterically (Figure 
3.4.3d).  
Figure 3.4.4 (a) Structure of the biotinylated derivative of cyclopeptide 24, synthesized on solid 
phase (b,c) In vitro pull down assay using biotinylated cyclopeptide 2, visualized by SDS-PAGE 
and followed by western blot analysis using antibodies against human EZH2 (b) and human EED 
and SUZ12 (c). 
 
The results of a pull-down assay performed similarly to that previously described in 3.3, 
using a biotinylated derivative of 24 synthesized on solid phase, also showed that our stapled 
peptide binds to Suz12 specifically and selectively, which strengthen the validation of our initial 
hypothesis, thus strongly suggesting that compound 24 does target SUZ12 and likely inhibits 
PRC2 function by  prevent its colocalization to the nucleosomes.  
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Given such encouraging results, we next investigated the feasibility of using compound 24 
in functional assays, by exploring both its proteolytic stability and its cell penetrating properties.  
Proteolytic stability was studied by subjecting peptide 24 to a chymotrypsin stability assay. For 
comparison, we also studied its linear counterpart 13 in the same conditions. HPLC and LC/MS 
analysis showed marked protection of 24 to proteolysis (t1/2 = 20.5 h), in contrast to its respective 
linear analogue, which was fully degraded in half an hour (t1/2 = 0.5 h). We further tested the 
stability of cyclopeptide 24 and its parent linear sequence 13 in plasma. In line with the 
chymotripsin assay results, our macrocycle showed high resistance to proteolysis in these 
conditions, resulting also markedly superior to peptide 13, which was fully degraded after 30 
minutes (Figure 3.4.5).   
 
Figure 3.4.5 Both Chymotrypsin-based proteolytic degradation and the plasma assay show 
enhanced stability of our i, i+4 bisthioether stapled peptide 24, as compared to its linear parent 
peptide 13. 
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Cellular uptake was studied by live confocal microscopy using a fluorescently labeled 
derivative of 24. Notably, confocal imaging after incubation of Caki-1 cells with FITC-tagged 24 
showed its favorable cell penetrating properties, and more importantly that it localizes mainly in 
the nuclei, where the targeted PRC2 complex is located (Figure 3.4.6). 
Figure 3.4.6 Confocal microscopy images of Caki-1 cells, scale bar 10 m. Cells were treated 
with FITC-labeled 24 (24-FITC, 5 M) and control peptide (-Ala--Ala-FITC, 5 M) at 37oC 
for 5h. 
We next demonstrated the ability of cyclopeptide 24 to target and functionally block PRC2-
mediated H3K27 methylation in cells. For this purpose, we treated Caki-1 cells for 72h with 
varying concentrations of 24 and analyzed all degrees of methylation on H3K27 by western blot 
from histone extracts. We used GSK126 (1 M, 10 nM) and the linear wild type peptide sequence 
13 (10 M, 50 M) as positive and negative control, respectively.  The results showed a clear 
concentration-dependent inhibition of H3K27me3 (Figure 3.4.7a). Further quantitation by an 
absorbance-based colorimetric assay yielded an IC50 of 1.36  1.14 M, similar to that obtained in 
Brightfield Nuclei + Cytoskeleton
FITC Overlay (FITC+Nuclei)
Brightfield Nuclei + Cytoskeleton
FITC Overlay (FITC+Nuclei)
Cells treated with FITC-labeled derivate of 24 Cells treated with control peptide, ! -Ala-! -Ala-FITCa b
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our enzymatic functional assay (Figure 3.4.7b). This data confirmed that our stapled peptide is cell 
permeable and a potent inhibitor of relevant physiological methylation of the PRC2 substrate. 
We also tested the selectivity of compound 24 for PRC2 methyltransferase activity, by 
monitoring its effect on several others post-translational modifications. Our stapled peptide 
showed exquisite selectivity for H3K27Me3 inhibition. Thus, treatment of caki-1 cells with either 
high concentration of 24 (5 M) or vehicle, and subsequent western blot analysis of histones 
isolated from the cell lysate, indicated no effect on H3K4me3, H3K9me3, H3K36me2, H3K79me2 
and H3K27Ac. On the other hand, total inhibition of H3K27me3 was observed in the same 
experimental conditions (Figure 3.4.7c). Altogether, this data demonstrates that our stapled peptide 
24 is resistant to proteolysis, cell permeable and a potent selective inhibitor of the relevant 
physiological methylation substrate of PRC2.  
Finally, we studied the impact of H3K27m3 inhibition on proliferation and growth of Caki-
1 cells, using healthy lung fibroblast cells IMR90 and GSK126 as a negative and positive controls, 
respectively. Proliferation was determined after treating the cells with compound 24, GSK126 or 
an equimolar mixture of both compounds for 72h, adding a fresh dose of compound every 24h. 
Remarkably, these assays indicated that our compound is able to significantly arrest Caki-1 cells 
growth, with an IC50 value of 2.06  1.26 M (Figure 3.4.7d). More notably, a combination of 
both compounds yielded an IC50 value of 0.82  0.17M, which also suggest a marked synergistic 
anti-proliferative effect. This result is in line with the data previously obtained from our 
H3K27me3 enzymatic inhibition assay. Importantly, no cytotoxicity was observed below 100M 
in non-cancerous human fibroblast IMR90 cells.  
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Figure 3.4.7 (a) Western blot analysis shows dose-dependent response of H3K27me3 within 
metastatic human clear-cells renal carcinoma cells (Caki-1), after treatment with stapled peptide 
24 once daily for 72h. Single concentration treatment with GSK126 (positive control) and linear 
wild type sequence 13 (negative control) in the same experimental conditions are also shown. (b) 
Quantitation of H3K27me3 using and absorbance-based colorimetric assay yielded an IC50 value 
of 1.36  1.14 M. Protein loading was accurately corrected by measuring total H3 using an 
absorbance-based colorimetric assay. (c) Selectivity of H3K27 trimethylation inhibition over a 
broad panel of histone post-translational modifications. Cells were treated with stapled peptide 24 
(5 M) or vehicle, once daily for 72h. (d) Treatment of Caki-1 cells with cyclopeptide 24 
significantly inhibits cell proliferation. Proliferation was measured after 72h of daily treatment 
with the correspondent compound. The data is presented as a mean of two independent 
experiments each with triplicate measurements.  
 
 
In summary, we have exploited our solid phase synthetic approach to generate a series of 
stapled peptide capable of effectively disrupt a biologically relevant intracellular PPI. In particular, 
we describe the design, synthesis and biological evaluation of stapled peptide inhibitors of PRC2 
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methyltransferase activity, designed to target a crucial interface in PRC2, formed by the nurf55 
and the SUZ12-NBE domains. Compared to their linear counterpart, most of these compounds 
showed enhanced -helical structure and inhibition of target function. In particular, our lead 
cyclopeptide 24 resulted a potent inhibitor of H3K27 trimethylation in both in vitro and cellular 
assays, demonstrating that it is cell permeable and active in physiological conditions. Inhibition of 
PRC2 catalytic activity by this compound produced a marked dose-dependent antiproliferative 
effect in metastatic Cakis-1 cells. Confocal microscopy has further illustrated that cyclopeptide 24 
is not only cell permeable, but also able to reach the nuclei, where the PRC2 complex is localized. 
Our studies also provide strong evidences suggesting that our stapled peptide 24 is an allosteric 
inhibitor of PRC2 function, and therefore, this compound may well be the first inhibitor of SUZ12-
NBE described to date. 
 
3.5 EXPERIMENTAL SECTION 
3.5.1 General experimental information 
Solid Phase Peptide Synthesis.  
All peptides were manually synthesized on 4-alkoxy-2,6-dimethoxybenzyl- amine resin 
(PAL, 0.5mmol/g). Coupling steps were performed under Microwave irradiation, using a 
combination of PyBOP/Oxyme as coupling reagents. Fmoc deprotection was accomplished at 
room temperature with a piperidine solution, 20% in DMF. 
 
4-methoxytrityl (Mmt) Deprotection and Maleimide test.  
Mmt deprotection was carried out with a deprotection solution (15mL per 0.5g of resin, 2% 
TFA, 10% TIS, 88% DCM) at room temperature for 5 min. The resin was then washed with DCM 
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(5X) and treated repeatedly with the same solution until its color changed from orange to light 
yellow. Maleimide test was next performed (Scheme S4). To this end, a small aliquot of Mmt 
deprotected resin was neutralized with 3mL of 5% DIEA in DMF for 5 min, and washed with 
DMF (2 mL, 3X), DCM (3 mL, 3X) and DMF (3 mL, 2X). The neutralized clean resin was 
subsequently mixed with N-methylmaleimide (5 eq. from a 20 mg/mL DMF stock solution), and 
DIEA (5 eq.) in a 2-mL microwave vial with a stir-bar, and reacted under microwave irradiation 
at 85 oC for 15 min. Next, the suspension was transferred into a SPPS vessel, washed (DMF 2 mL 
3X, DCM 2 mL 3X) and treated with the proper cleavage cocktail. The resulting peptide is finally 
precipitated/washed with cold diethyl ether and analyzed by LC/MS to quantitate the extent of the 
deprotection step (Scheme S4). If the Mmt-deprotection is incomplete, additional deprotection 
rounds are repeated until completion of the reaction. After total Mmt removal is achieved, the resin 
is neutralized with 5% DIEA in DMF for 5 min, washed with DMF (3X) and DCM (3X), and dried 
under vacuum for storage or used directly for the cyclization step. 
 
Stapling Reaction.  
The resin containing the precursor Cys-thiol free linear peptide was transferred into a 
microwave reaction vial containing a stir-bar, to which NaI (100 eq for i+7 sequences, 17.5 eq for 
i+4 sequences) and DMF (1 mL per 20 mg of resin for i+7 sequences, 1mL per 10mg of resin for 
i+4 sequences) were added subsequently, while keeping the mixture stirring at all times, followed 
by TCEP (3 eq for i+7 sequences, 0.5 eq for i+4 sequences, from an aqueous stock solution of 300 
mg/mL). The vial was then capped with a MW vial cap equipped with a rubber septum and the 
resulting suspension bubbled under N2 for 15 min. Next, DIEA (35 eq.) was added (by syringe), 
keeping the stirring under N2 for another 30 min, after which, the dibromoalkyl electrophile was 
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injected (20 eq for i+7 sequences, 3.5 eq for i+4 sequences). The suspension is finally reacted 
under microwave irradiation for 2 min at 125oC, transferred into the SPPS reaction vessel and 
washed with water (5 X, soak if necessary to remove residual NaI), DMF (5 X) and DCM (5 X). 
The efficiency of the stapling step was confirmed by cleaving a small aliquot of resin and analyzing 
the precipitated/washed peptide pellet by LC/MS and HPLC.  
 
3.5.2 Biochemical and Cellular Studies 
Circular Dichroism (CD) 
Circular dichroism spectra were recorded on a ChirascanTM spectrometer. Peptides were 
dissolved in deionized water, at a concentration of 25 M. CD signal was monitored at 1nm 
intervals from 180 to 260 nm with a 1-mm path quartz cuvette.  The data reported is the average 
of three scans, subtracting the background. The helical content of each peptide was determined 
using prism 7 software, with molar ellipticity [] [deg·cm2·dmol-1] being calculated using the 
following formula: [θ]  =  1000000θ/(C  #of residues  l), where  is the ellipticity read out 
from Chirascan, C is the concentration of peptide samples in M, l is the pathlength of the cuvette 
measured in mm. The percentage helicity was calculated with formula: %Hellicity = 100  
[θ]222/[θ]max222, where [θ]max222 = -31500  [1- (2.5# of residues)]}.[2] 
 
Chymotrypsin Stability Test 
Assays were performed using freshly prepared α-chymotrypsin from bovine pancreas type 
II, ≥ 40 U/mg. The enzyme was initially reconstituted in HCl 1M (1 g/L), and kept in ice until 
used.  Peptides stock solutions were prepared in assay buffer (50 mM Tris·HCl pH=8.0, 560 μM 
calcium chloride, 0.1% Tween-20) containing <3% of DMSO. The reactions were performed at a 
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200 L scale, in assay buffer, at final concentrations of 50 M for peptide and 60 M for α-
chymotrypsin (10 L from the reconstitution solution). The mixture was incubated at 37 °C and 
aliquots were withdrawn in portions of 25 L at different time points for analysis. The removed 
aliquots were mixed with 25 uL of water 1% TFA, and then treated with a column for detergent 
removal following the manufacturer’s protocol (Pierce, Catalog #:87776). The rate of peptide 
proteolysis was monitored by HPLC and HPLC-MS analysis. Control experiments were carried 
out under the same conditions but using BSA instead of α-chymotrypsin. 
 
Plasma Stability Test 
1mM stock solution of the corresponded peptide was prepared in PBS buffer (pH 7.4). 
Next, 50 L from this solution were added to 1 mL of human plasma (Sigma-Aldrich, P9523). The 
mixture was incubated at 37 oC with mechanical shaking at 300 rpm. Aliquots were withdrawn in 
portions of 150 L at different time points for analysis and mixed with 60 L ACN/EtOH (1:1 v/v) 
for plasma protein precipitation. After centrifugation at 12000 rpm for 5 min, the supernatant was 
collected and analyzed by HPLC and HPLC-MS. 
 
Enzymatic Functional Assay to Quantify Inhibition of H3K27me3. 
All peptide candidates were evaluated for their ability to inhibit H3K27 trimehtylation in 
vitro with an EpiQuik Histone Methyltransferase Activity/Inhibition Assay Kit (H3K27) (Epigentek, 
P-3005). The enzymatic reactions were performed using PRC2 complex extracted as a component 
of the nuclear extracts from a human clear cell renal carcinoma cell line (Caki-1).  Protein 
concentration in the nuclear extracts was first optimized in order to have the suitable concentration 
of functional PRC2 to produce a strong signal (Control, A=0.9) with a reliable assay window 
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(Blank, A=0.15). The assays were validated by using GSK-126, a well-characterized Ezh2 
inhibitor, as a positive control. The trimethylation reaction was performed in vitro using 
immobilized recombinant oligonucleosomes and then quantified by absorbance, following the 
manufacturer’s protocol. Experiments were carried out using several concentrations of inhibitors, 
always including a 100% inhibition control of 0.1 M GSK126. The data were fit into a standard 
Langmuir isotherm for inhibition, and are the result of the average and standard deviation of three 
independent experiments. 
 
Cell Culture 
Metastatic human clear cell renal carcinoma cell line (Caki-1) were used to extract the 
active PRC2 complex used in the enzymatic assays. Caki-1 cells and healthy control lung fibroblast 
cell (IMR90) cell lines were used to study the cytotoxic activity of compounds 9, 10, GSK126 and 
24. The cells were all obtained from the American Type Culture Collection (ATCC) (Manassas, 
VA). All of the cells were grown adherently. The Caki-1 cells were cultured in Roswell Park 
Memorial Institute (RPMI-1640) (Mediatech Inc., Manassas, VA) medium, while IMR90 cells 
were maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Mediatech Inc., Manassas, 
VA); all media were supplemented with 10% foetal bovine serum (FBS, Life Technologies, Grand 
Island, NY), 1% Minimum Essential Media (MEM) nonessential amino acids (Mediatech), and 1% 
penicillin−streptomycin (Mediatech). All cells were cultured at 37 °C under 5% CO2 and 95% air 
in a humidified incubator.  
 
Nuclear Extraction 
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Active PRC2 was isolated as a component of the nuclear extracts from Caki-1 cells, using 
EpiQuik Nuclear Extraction kit (Epigentek OP-0002-1) and following the manufacturer’s protocol. 
 
Inhibition of H3K27me3 in Caki-1 Cells. 
The ability of our cyclopeptides to inhibit H3K27me3 in cells was studied by treating Caki-
1 cells with different concentrations of the corresponding stapled peptide containing a maximum 
DMSO concentration of 1%. The cells were treated for 72h, fresh cyclopeptide solution was 
provided every 24h. Wild type linear peptides (100 M and 25 M), GSK126 (1 M) and media 
containing 1% DMSO were used as controls. After treatment, the cells were lysed and the histone 
extracted using the EpiQuik Total Histone Extraction Kit (Epigentek OP-0006-100), following the 
instructions provided by the manufacturer. Total H3 concentrations were then measured for all the 
extracted samples using the EpiQuik Total Histone H3 Quantification Kit (Colorimetric, P-3062). 
Finally, trimethylation levels were evaluated by Western blot. To this end, 10 ng of each histone 
extract lysate were added on a 12% Mini-PROTEAN® TGX™ Precast Gels (Biorad). 
Electrophoresis was then carried out with Mini-PROTEAN® Tetra Vertical Electrophoresis Cell 
(Biorad) at 200 V for 30 min. Next, protein bands were transferred onto Nitrocellulose Memberane 
(Biorad, 0.2 m) with Trans-blot SD Cell (Biorad) at 150 mA for 45 min. Downstream process of 
the memberane included blocking (50% Li-COR Odyssey Blocking Buffer PBS, 60 min at RT 
on orbital shaker), incubation with primary antibody (Cell Signaling: Tri-methyl-H3K27 Rabbit 
mAb #9733, and Histone H3 mouse mAb #3638, overnight at 4 oC), washing with PBST buffer, 
and incubation with secondary antibody (IRDye® 800CW Donkey anti-Mouse IgG, and IRDye® 
800CW Donkey anti-Rabbit IgG) at RT for 60 min on an orbital shaker. Blotting imagines were 
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obtained with Odyssey FC Imaging System (700 nm channel for H3K27me3 and 800 nm channel 
for H3). 
Alternatively, the levels of H3K27me3 in the extracted histones were quantified using the 
EpiQuick Global Tri-methyl Histone H3K27 Quantification Kit (Colorimetric, Epigentek P-3042). 
The calculated values were normalized to the previously determined values for the corresponding 
total H3. The data were fit into a standard Langmuir isotherm for inhibition, and are the result of 
the average and standard deviation of three independent experiments. 
 
Confocal Microscopy 
Caki-1 cells (0.8 x 105 cells/well) were cultured for 24h on Millicell EZ SLIDE 
(Milliporesigma, PEZGS0416) in 1 mL complete RPMI supplemented with 10% FBS and 2 mM 
L-glutamine, 1% Minimum Essential Media (MEM) nonessential amino acids (Mediatech), and 
1% penicillin−streptomycin (Mediatech). The cells were then seeded, on fresh medium, with 
fluorescent peptide (final concentration 5 M, 1% DMSO) or vehicle (1% DMSO) and incubated 
for 5h at 37 °C under 5% CO2 and 95% air in a humidified incubator. Next, the medium was 
removed, and each well washed with 1 mL PBS (3X, 5min each time), followed by fixation with 
4% paraformaldehyde in PBS (500 L, Alfa Aesar), at room temperature for 15 min. After removal 
of the fixation solution, the slides were washed with PBS (3X, 5min each time) and the nucleus of 
the cells stained with 250 μL of DAPI solution (1μg/mL in PBS, Sigma-Aldrich, 28718-90-3) at 
room temperature for 10 min. The DAPI solution was next aspirated, the wells were washed with 
PBS (3X, 5min each time), and the cellular skeleton was stained with Alexa Fluor 555 Phalloidin 
following the manufacturer protocol. Subsequently, the slides were washed with PBS (3X, 5min 
each time), before adding 20 μL of mounting medium (Prolong Gold, Invitrogen, P10144) into 
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each well, following the manufacturer’s protocol. The slides were kept in the dark for 24 hours 
before imaging. The cells were visualized with an Olympus Fluoview microscope (model number: 
FV10i). 
 
Antiproliferative assays.  
Cells were seeded at a concentration of 0.15*106 cells/well in 3 mL of RPMI supplemented 
with 10% FBS and 2 mM L-glutamine, 1% Minimum Essential Media (MEM) nonessential amino 
acids (Mediatech), and 1% penicillin−streptomycin (Mediatech) into tissue culture grade 6-well 
flat bottom plates (Fisher Scientific, Waltham, MA) and grown for 24 h at 37 °C under 5% CO2 
and 95% air in a humidified incubator. Following seeding, the cyclopeptides were dissolved in 
DMSO and diluted in media before addition to cell culture medium at a maximum DMSO 
concentration of 1%, at cyclopeptide concentrations ranging from 0.01μM to 1.5 μM. For the 
following 72h, every 24 h the cell culture media was changed and fresh media containing the 
compounds was added, 1% DMSO was used as control. After 72h of treatment, both floating and 
attached cells were collected and analysed. NucleoCounter NC-3000™chamber (Chemometec, 
Allerod, Denmark) was used to determine total cell number and viability according to the 
manufacturer’s protocol. 
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3.6 APPENDIX 
(1) Ac-TVDKIASALSVLAEEVPQN-CONH2  
 
HRMS (ESI) (m/z): [M] cacld. for C88H149N23O31, 2024.0790 
         [M+2H]2+ found 1013.0458 (monoisotopic peak) 
HPLC: Method 4, tR = 12.03 min. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HPLC: Crude Reaction 
HRMS: Crude Reaction 
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(2) Ac-TVD[CIASC]C3LSVLAEEVPQN-CONH2  
 
 
 
 
 
HRMS (ESI) (m/z): [M] cacld. for C88H146N22O31S2, 2070.9966 
      [M+2H]2+ found 1036.5039 (monoisotopic peak) 
HPLC: Method 4 , tR = 15.73 min. 
 
 
DMSO peak 
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(3) Ac-TVD[CIASC]C5LSVLAEEVPQN-CONH2  
 
 
 
 
 
HRMS (ESI) (m/z): [M] cacld. for C90H150N22O31S2, 2099.0279 
         [M+2H]2+ found 1050.5099 (monoisotopic peak) 
HPLC: Method 4, tR = 17.11 min. 
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(4) Ac-TVDKIASA[CSVLAEEC]C6PQN-CONH2  
 
 
 
 
 
 
HRMS (ESI) (m/z): [M] cacld. for C89H149N23O31S2 2100.0231 
         [M+2H]2+ found 1051.0099 (monoisotopic peak) 
HPLC: Method 4, tR = 14.14 min. 
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(5) Ac-TVDKIASA[CSVLAEEC]C7PQN-CONH2  
 
 
 
 
  
 
HRMS (ESI) (m/z): [M] cacld. for C90H151N23O31S2 2114.0388 
         [M+2H]2+ found 1058.0263 (monoisotopic peak) 
HPLC: Method 4, tR = 15.53 min. 
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(6) Ac-TVDKIASA[CSVLAEEC]C8PQN-CONH2  
 
 
 
 
 
 
Synthesis: Using 1,8-dibromooctane as electrophile 
HRMS (ESI) (m/z): [M] cacld. for C91H153N23O31S2 2128.0544 
           [M+2H]2+ found 1065.0344 (monoisotopic peak) 
HPLC: Method 4, tR = 16.47 min. 
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(7) Ac-EWLREKTITQIEEF-CONH2  
 
Synthesis: Isolated from 13, after subsequent TFA cleavage, Scheme S2.1 
HRMS (ESI) (m/z): [M] cacld. for C85H131N21O26, 1861.9574 
         [M+2H]2+ found 931. (monoisotopic peak) 
HPLC: Method 4, tR = 12.22 min. 
 
 
 
HPLC: After 
HRMS: After 
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(8) Ac-EWL[CEKTC]C3TQIEEF-CONH2  
 
Synthesis: Using 1,3-dibromopropane as electrophile, Scheme S2.1 
HRMS (ESI) (m/z): [M] cacld. for C82H122N19O26S2, 1838.8219 
         [M+1H]+ found 1839.8307 (monoisotopic peak) 
HPLC: Method 4, tR = 13.67 min. 
 
 
 
 
 
 
HPLC: After 
HRMS: Crude Reaction Mixture After 
  117 
(9) Ac-EWL[CEKTC]C5TQIEEF-CONH2  
 
Synthesis: Using 1,5-dibromopentane as electrophile, Scheme S2.1 
HRMS (ESI) (m/z): [M] cacld. for C84H126N18O26S21866.8532 
      [M+1H]+ found 1867.8811 (monoisotopic peak) 
HPLC: Method 4 , tR = 14.51 min. 
 
 
HPLC: After 
HRMS: Crude Reaction Mixture After 
  118 
(10) Ac-LCRNFMLHLVSMHDFLI-CONH2  
 
Isolated from 16 after subsequent TFA and t-Bu cleavages, Scheme S2.2 
HRMS (ESI) (m/z): [M] cacld. for C97H152N26O22S3, 2129.0737 
         [M+2H]2+ found 1065.5472 (monoisotopic peak) 
HPLC: Method 4, tR = 15.14 min. 
 
 
 
 
 
 
 
 
 
 
HPLC: After 
HRMS: Crude Reaction Mixture After 
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(11) Ac-LCRNFMLHLVSMHDFLI-CONH2  
 
Synthesis: Using 1,3-dibromopropane as electrophile, Scheme S2.2 
HRMS (ESI) (m/z): [M] cacld. for C91H146N26O22S5, 2114.9709 
         [M+2H]2+ found 1058.4900 (monoisotopic peak) 
HPLC: Method 4, tR = 13.14 min. 
HPLC: After 
HRMS: Crude Reaction Mixture After 
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FITC--Ala--Ala -LCRN[CMLHC]C3VSMHDFLI-CONH2 (FITC-17) 
 
Synthesis: Using 1,3-dibromopropane as electrophile, Scheme S1.3 
HRMS (ESI) (m/z): [M] cacld. for C117H167N29O28S6, 2604.0703. 
      [M+2H]+ found  1303.0373 (monoisotopic peak) 
HPLC: Method 4, tR =  15.79 min. 
 
FITC--Ala--Ala-CONH2 
 
HRMS (ESI) (m/z): [M] cacld. for C27H24N4O7S, 548.1366 
      [M+2H]+ found  548.1646 (monoisotopic peak) 
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(12) Ac-LCRNFMLHLVSMHDFLI-CONH2  
Synthesis: Using 1,5-dibromopentane as electrophile, Scheme S2.2 
HRMS (ESI) (m/z): [M] cacld. for C93H150N26O22S5 2143.0022 
      [M+1H]+ found 1072.5054 (monoisotopic peak) 
HPLC: Method 4 , tR = 13.98 min. 
 
 
HPLC: After 
HRMS: Crude Reaction Mixture After 
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(13) Ac-VINEEYKIWKKNTPFL-NH2  
 
HRMS (ESI) (m/z): [M] cacld. for C99H151N23O25, 2062.1251 
                  [M+2H]2+ found 1032.0691 (monoisotopic peak) 
HPLC: Method 1, tR = 10.81 min. 
 
 
(14) Ac-VI[CEEYC]C3IWKKNTPFL-NH2 
HRMS (ESI) (m/z): [M] cacld. 
for C98H147N21O24S2, 2066.0369 
[M+2H]2+ found 1034.0256 
(monoisotopic peak) 
HPLC: Method 4, tR = 12.73 
min. 
 
 
(15) Ac-VI[CEEYC]C4IWKKNTPFL-NH2 
HRMS (ESI) (m/z): [M] cacld. 
for C99H149N21O24S2, 2080.0526 
[M+2H]2+ found 1041.0312 
(monoisotopic peak) 
HPLC: Method 2, tR = 16.56 
min. 
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(16) Ac-VI[CEEYC]C4eneIWKKNTPFL-NH2 
HRMS (ESI) (m/z): [M] cacld. 
for C99H147N21O24S2, 2078.0369 
[M+2H]2+ found 1040.0259 
(monoisotopic peak) 
HPLC: Method 1, tR = 14.75 
min. 
 
 
(17) Ac-VI[CEEYC]C5IWKKNTPFL-NH2 
HRMS (ESI) (m/z): [M] cacld. 
for C100H151N21O24S2, 2094.0682 
[M+2H]2+ found 1048.0977 
(monoisotopic peak) 
HPLC: Method 2, tR = 16.94 
min. 
 
 
(18) Ac-VI[CEEYC]C6IWKKNTPFL-NH2 
HRMS (ESI) (m/z): [M] cacld. 
for C101H152N21O24S2, 2108.0839 
[M+2H]2+ found 1055.5736 
(monoisotopic peak) 
HPLC: Method 1, tR = 13.96 
min. 
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(19) Ac-VINEEY[CIWKC]C3NTPFL-NH2 
HRMS (ESI) (m/z): [M] cacld. for 
C96H141N21O25S2, 2051.9849 
[M+2H]2+ found 1026. 9989 
(monoisotopic peak) 
HPLC: Method 2, tR = 15.10 min. 
 
 
 
(20) Ac-VINEEY[CIWKC]C4NTPFL-NH2 
HRMS (ESI) (m/z): [M] cacld. for 
C97H143N21O25S2, 2066.0005 
[M+2H]2+ found 1034.5075 
(monoisotopic peak) 
HPLC: Method 4, tR =  12.30 min. 
 
 
 
(21) Ac-VINEEY[CIWKC]C4eneNTPFL-NH2 
HRMS (ESI) (m/z): [M] cacld. for 
C97H141N21O25S2, 2063.9849 
[M+2H]2+ found 1032.9973 
(monoisotopic peak) 
HPLC: Method 1, tR =  13.68 min. 
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(22) Ac-VINEEY[CIWKC]C5NTPFL-NH2 
HRMS (ESI) (m/z): [M] cacld. for 
C98H145N21O25S2, 2080.0162 
[M+2H]2+ found 1041.0148 
(monoisotopic peak) 
HPLC: Method 2, tR = 16.01 min. 
 
 
 
(23) Ac-VINEEY[CIWKC]C6NTPFL-NH2 
HRMS (ESI) (m/z): [M] cacld. for 
C99H147N21O25S2, 2094.0318 
[M+2H]2+ found 1048.0480 
(monoisotopic peak) 
HPLC: Method 1, tR = 16.94  min. 
 
 
 
(24) Ac-V[CNEEC]C3KIWKKNTPFL-NH2 
HRMS (ESI) (m/z): [M] cacld. 
for C93H145N23O24S2, 2032.0274 
[M+2H]2+ found 1017.0219 
(monoisotopic peak) 
HPLC: Method 2, tR = 10.91 
min. 
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(25) Ac-V[CNEEC]C4KIWKKNTPFL-NH2 
HRMS (ESI) (m/z): [M] cacld. 
for C94H147N23O24S2, 2046.0431 
[M+2H]2+ found 1024.0316 
(monoisotopic peak) 
HPLC: Method 2, tR = 11.64 
min. 
 
(26) Ac-V[CNEEC]C4eneKIWKKNTPFL-NH2 
HRMS (ESI) (m/z): [M] cacld. 
for C94H145N23O24S2, 2044.0274 
[M+2H]2+ found 1023.0231 
(monoisotopic peak) 
HPLC: Method 1, tR = 9.81 
min. 
 
(27) Ac-V[CNEEC]C5KIWKKNTPFL-NH2 
HRMS (ESI) (m/z): [M] cacld. 
for C95H149N23O24S2, 2046.0431 
[M+2H]2+ found 1031.0359 
(monoisotopic peak) 
HPLC: Method 2, tR = 12.11 
min. 
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(28) Ac-V[CNEEC]C6KIWKKNTPFL-NH2 
HRMS (ESI) (m/z): [M] cacld. 
for C96H151N23O24S2, 2046.0431 
[M+2H]2+ found 
1038.0455(monoisotopic peak) 
HPLC: Method 2, tR = 13.28 
min. 
 
(29) Ac-VINEEYKIWKKN[CPFLC]C3-NH2 
HRMS (ESI) (m/z): [M] cacld. 
for C104H158N24O25S2, 2207.1271 
[M+2H]2+ found 1104.5690 
(monoisotopic peak) 
HPLC: Method 1, tR = 10.90 
min. 
 
 
(30) Ac-VINEEYKIWKKN[CPFLC]C4-NH2 
HRMS (ESI) (m/z): [M] cacld. for 
C105H158N24O25S2, 2221.1428 
[M+2H]2+ found 1111.5768 
(monoisotopic peak) 
HPLC: Method 1, tR = 15.21min. 
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(31) Ac-VINEEYKIWKKN[CPFLC]C4ene-NH2 
HRMS (ESI) (m/z): [M] cacld. 
for C105H158N24O25S2, 2219.1271 
[M+2H]2+ found 1110.5683 
(monoisotopic peak) 
HPLC: Method 1, tR = 13.25min. 
 
 
 
(32) Ac-VINEEYKIWKKN[CPFLC]C5-NH2 
HRMS (ESI) (m/z): [M] cacld. 
for C106H162N24O25S2, 2219.1271 
[M+2H]2+ found 1118.5822 
(monoisotopic peak) 
HPLC: Method 1, tR = 11.00 min. 
 
 
 
(33) Ac-VINEEYKIWKKN[CPFLC]C6-NH2 
HRMS (ESI) (m/z): [M] cacld. 
for C107H164N24O25S2, 2249.1741 
[M+2H]2+ found 
1125.5899(monoisotopic peak) 
HPLC: Method 1, tR = 13.48 min. 
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Chapter IV. Summary 
4.1  Summary 
 A new method to accessing bisthioether stapled peptides on solid support was discovered 
and optimized. Its versatility and efficiency were demonstrated by applying it to the 
synthesis of stapled peptides of multiple architectures. This approach allows for 
crosslinking of natural cysteine residues with a variety of hydrocarbon spacers and without 
harsh reaction conditions and expensive/toxic transition metal catalysts or radical initiators. 
It is also the only available synthetic method that allows bisthioether stapling on sequences 
containing several cysteine residues and the chemoselective incorporation of multiple 
bisthioether staples over the same sequence.  
 We have identified three families of novel allosteric inhibitors of PRC2 function. The first 
series was designed to target a key intramolecular interaction in EZH2, the catalytic subunit 
of the complex, taking place between its SBD and SANT1L-l domains. The second family 
of cyclopeptides has been designed to mimic a VEFS helix of SUZ12 and therefore disrupt 
its binding with the EZH2-SANT2 domain, another crucial binary complex needed for the 
proper assembly of PRC2 in its catalytically bioactive conformation. The third series 
targets an alpha helical interaction between Nurff55 and SUZ12, which plays a key role in 
the complex recruitment onto nucleosomes and thus in its H3K27 methyltransferase 
activity. These three families of stapled peptides constitute the first allosteric inhibitors of 
PRC2 activity targeting such protein interfaces.  
 The biological data presented herein demonstrate that our lead cyclopeptides 2, 11 and 24 
are potent inhibitors of H3K27 trimethylation in both in vitro and cellular assays, and hence 
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cell permeable and active in physiological conditions. In addition, inhibition of PRC2 
catalytic activity by these compounds produces a marked dose-dependent antiproliferative 
effect in metastatic Cakis-1 cells. Notably, in these experiments our stapled peptides were 
almost as effective as GSK126, an EZH2 inhibitor currently in clinical development.113 
The allosteric nature of our inhibitors could make them highly valuable to address the 
resistance profiles recently reported in clinical trials of three EZH2-SET domain inhibitors, 
in which extended dosing of these drugs have led to secondary EZH2 mutants resistant to 
treatment.113 Our compound’s unique mechanism of PRC2 inhibition, together with its 
potency, remarkable H3K27me3 inhibition selectivity, and low cytotoxicity to non-
cancerous cells demonstrate these stapled peptide’s potential for future development of 
novel epigenetic cancer therapies.  
 The success achieved in the development of allosteric PRC2 inhibitors validate the utility 
of the synthetic methodology initially presented herein, and also the potential of 
bisthioether stapled peptides as peptidomimetic molecules useful to target intracellular 
undruggable protein-protein interactions of biological relevance. 
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